MMP-13 inhibitors

Connecting via Winsock to STN

Welcome to STN International! Enter x:x

LOGINID:SSPTAEXO1623

PASSWORD:
TERMINAL (ENTER 1, 2, 3, OR ?):2

* * * * * * * * * * Welcome to STN International * * * * * * * * * *

NEWS	1		Web Page URLs for STN Seminar Schedule - N. America
NEWS	2		"Ask CAS" for self-help around the clock
NEWS	3	DEC 21	IPC search and display fields enhanced in CA/CAplus with the IPC reform
NEWS	4	DEC 23	New IPC8 SEARCH, DISPLAY, and SELECT fields in USPATFULL/ USPAT2
NEWS	5	JAN 13	IPC 8 searching in IFIPAT, IFIUDB, and IFICDB
NEWS	6	JAN 13	New IPC 8 SEARCH, DISPLAY, and SELECT enhancements added to INPADOC
NEWS	7	JAN 17	Pre-1988 INPI data added to MARPAT
NEWS	8	JAN 17	IPC 8 in the WPI family of databases including WPIFV
NEWS	9	JAN 30	Saved answer limit increased
NEWS	10	JAN 31	Monthly current-awareness alert (SDI) frequency added to TULSA
NEWS	11	FEB 21	STN AnaVist, Version 1.1, lets you share your STN AnaVist visualization results
NEWS	12	FEB 22	Status of current WO (PCT) information on STN
NEWS	13	FEB 22	The IPC thesaurus added to additional patent databases on STN
NEWS	14	FEB 22	Updates in EPFULL; IPC 8 enhancements added
NEWS	15	FEB 27	New STN AnaVist pricing effective March 1, 2006
NEWS	16	FEB 28	MEDLINE/LMEDLINE reload improves functionality
NEWS	17	FEB 28	TOXCENTER reloaded with enhancements
NEWS	18	FEB 28	REGISTRY/ZREGISTRY enhanced with more experimental spectral property data
NEWS	19	MAR 01	INSPEC reloaded and enhanced
NEWS	20	MAR 03	Updates in PATDPA; addition of IPC 8 data without attributes
NEWS	21	MAR 08	X.25 communication option no longer available after June 2006
NEWS	22	MAR 22	EMBASE is now updated on a daily basis

NEWS EXPRESS FEBRUARY 15 CURRENT VERSION FOR WINDOWS IS V8.01a,
CURRENT MACINTOSH VERSION IS V6.0c(ENG) AND V6.0Jc(JP),
AND CURRENT DISCOVER FILE IS DATED 19 DECEMBER 2005.
V8.0 AND V8.01 USERS CAN OBTAIN THE UPGRADE TO V8.01a AT
http://download.cas.org/express/v8.0-Discover/

NEWS HOURS STN Operating Hours Plus Help Desk Availability
NEWS LOGIN Welcome Banner and News Items

Enter NEWS followed by the item number or name to see news on that specific topic.

MMP-13 inhibitors

  * * * * * * * * * * * * * * STN Columbus * * * * * * * * * * * * * * *

FILE 'HOME' ENTERED AT 10:46:00 ON 30 MAR 2006

=>
Uploading
THIS COMMAND NOT AVAILABLE IN THE CURRENT FILE
Do you want to switch to the Registry File?
Choice (Y/n):
Switching to the Registry File...
Some commands only work in certain files. For example, the EXPAND
command can only be used to look at the index in a file which has an
index. Enter "HELP COMMANDS" at an arrow prompt (=>) for a list of
commands which can be used in this file.

=> FILE REGISTRY

COST IN U.S. DOLLARS	SINCE FILE ENTRY	TOTAL SESSION
FULL ESTIMATED COST	0.21	0.21

FILE 'REGISTRY' ENTERED AT 10:46:24 ON 30 MAR 2006
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.

Property values tagged with IC are from the ZIC/VINITI data file
provided by InfoChem.

STRUCTURE FILE UPDATES: 28 MAR 2006 HIGHEST RN 878378-71-3
DICTIONARY FILE UPDATES: 28 MAR 2006 HIGHEST RN 878378-71-3

New CAS Information Use Policies, enter HELP USAGETERMS for details.

TSCA INFORMATION NOW CURRENT THROUGH January 6, 2006

  Please note that search-term pricing does apply when
  conducting SmartSELECT searches.

```
**********************************************************************
*                                                                    *
* The CA roles and document type information have been removed from *
* the IDE default display format and the ED field has been added,    *
* effective March 20, 2005.  A new display format, IDERL, is now     *
* available and contains the CA role and document type information.  *
*                                                                    *
**********************************************************************
```

Structure search iteration limits have been increased. See HELP SLIMITS
for details.

REGISTRY includes numerically searchable data for experimental and
predicted properties as well as tags indicating availability of
experimental property data in the original document. For information
on property searching in REGISTRY, refer to:

http://www.cas.org/ONLINE/UG/regprops.html

=>
Uploading C:\Program Files\Stnexp\Queries\valdecoxib.str

MMP-13 inhibitors





chain nodes :
12 19 20 21 22
ring nodes :
1 2 3 4 5 6 7 8 9 10 11 13 14 15 16 17 18
chain bonds :
6-7 10-12 11-13 16-19 19-20 19-21 19-22
ring bonds :
1-2 1-6 2-3 3-4 4-5 5-6 7-8 7-11 8-9 9-10 10-11 13-14 13-18 14-15
15-16 16-17 17-18
exact/norm bonds :
7-8 7-11 8-9 9-10 10-11 16-19 19-20 19-21 19-22
exact bonds :
6-7 10-12 11-13
normalized bonds :
1-2 1-6 2-3 3-4 4-5 5-6 13-14 13-18 14-15 15-16 16-17 17-18

Match level :
1:Atom 2:Atom 3:Atom 4:Atom 5:Atom 6:Atom 7:Atom 8:Atom 9:Atom 10:Atom
11:Atom 12:CLASS 13:Atom 14:Atom 15:Atom 16:Atom 17:Atom 18:Atom 19:CLASS
20:CLASS 21:CLASS 22:CLASS

L1 STRUCTURE UPLOADED

=> s L1
SAMPLE SEARCH INITIATED 10:46:35 FILE 'REGISTRY'
SAMPLE SCREEN SEARCH COMPLETED - 47 TO ITERATE

100.0% PROCESSED 47 ITERATIONS 7 ANSWERS
SEARCH TIME: 00.00.01

FULL FILE PROJECTIONS: ONLINE **COMPLETE**
BATCH **COMPLETE**
PROJECTED ITERATIONS: 529 TO 1351
PROJECTED ANSWERS: 7 TO 298

L2 7 SEA SSS SAM L1

MMP-13 inhibitors

=> d L1 107
L1 HAS NO ANSWERS
L1 STR



Structure attributes must be viewed using STN Express query preparation.

=> d L1 1-7
L1 HAS NO ANSWERS
L1 STR



MMP-13 inhibitors

Structure attributes must be viewed using STN Express query preparation.

=> d L2 1-7

L2 ANSWER 1 OF 7 REGISTRY COPYRIGHT 2006 ACS on STN
RN 848124-98-1 REGISTRY
ED Entered STN: 08 Apr 2005
CN Benzamide, 2-chloro-5-[[2-[(2-hydroxyethyl)amino]ethoxy]methyl]-N-(tricyclo[3.3.1.13,7]dec-1-ylmethyl)-, mixt. with 4-(5-methyl-3-phenyl-4-isoxazolyl)benzenesulfonamide (9CI) (CA INDEX NAME)
MF C23 H33 Cl N2 O3 . C16 H14 N2 O3 S
CI MXS
SR CA
LC STN Files: CA, CAPLUS

CM 1

CRN 345304-10-1
CMF C23 H33 Cl N2 O3



CM 2

CRN 181695-72-7
CMF C16 H14 N2 O3 S



1 REFERENCES IN FILE CA (1907 TO DATE)
1 REFERENCES IN FILE CAPLUS (1907 TO DATE)

L2 ANSWER 2 OF 7 REGISTRY COPYRIGHT 2006 ACS on STN
RN 603151-46-8 REGISTRY
ED Entered STN: 13 Oct 2003
CN Benzenesulfonamide, 4-[5-methyl-3-[3-(methylsulfonyl)phenyl]-4-isoxazolyl]- (9CI) (CA INDEX NAME)
FS 3D CONCORD
MF C17 H16 N2 O5 S2

MMP-13 inhibitors

SR CA
LC STN Files: CA, CAPLUS



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

1 REFERENCES IN FILE CA (1907 TO DATE)
1 REFERENCES IN FILE CAPLUS (1907 TO DATE)

L2 ANSWER 3 OF 7 REGISTRY COPYRIGHT 2006 ACS on STN
RN 501093-54-5 REGISTRY
ED Entered STN: 01 Apr 2003
CN Benzenesulfonamide, 4-[3-(3-hydroxyphenyl)-5-methyl-4-isoxazolyl]- (9CI) (CA INDEX NAME)
FS 3D CONCORD
MF C16 H14 N2 O4 S
SR CA
LC STN Files: CA, CAPLUS



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

2 REFERENCES IN FILE CA (1907 TO DATE)
2 REFERENCES IN FILE CAPLUS (1907 TO DATE)

L2 ANSWER 4 OF 7 REGISTRY COPYRIGHT 2006 ACS on STN
RN 473311-73-8 REGISTRY
ED Entered STN: 12 Nov 2002
CN Benzenesulfonamide, 4-[3-(3,5-dimethylphenyl)-5-methyl-4-isoxazolyl]-2,5-difluoro- (9CI) (CA INDEX NAME)

MMP-13 inhibitors

OTHER NAMES:
CN 2,5-Difluoro-4-[3-(3,5-dimethylphenyl)-5-methylisoxazol-4-yl]benzenesulfonamide
FS 3D CONCORD
MF C18 H16 F2 N2 O3 S
SR CA
LC STN Files: CA, CAPLUS, TOXCENTER, USPAT2, USPATFULL



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

1 REFERENCES IN FILE CA (1907 TO DATE)
1 REFERENCES IN FILE CAPLUS (1907 TO DATE)

L2 ANSWER 5 OF 7 REGISTRY COPYRIGHT 2006 ACS on STN
RN 473308-32-6 REGISTRY
ED Entered STN: 12 Nov 2002
CN Benzenesulfonamide, 4-[3-(3-chloro-4-methoxyphenyl)-5-methyl-4-isoxazolyl]-2,6-difluoro- (9CI) (CA INDEX NAME)
OTHER NAMES:
CN 2,6-Difluoro-4-[3-(3-chloro-4-methoxyphenyl)-5-methylisoxazol-4-yl]benzenesulfonamide
FS 3D CONCORD
MF C17 H13 Cl F2 N2 O4 S
SR CA
LC STN Files: CA, CAPLUS, TOXCENTER, USPAT2, USPATFULL



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

1 REFERENCES IN FILE CA (1907 TO DATE)

MMP-13 inhibitors

1 REFERENCES IN FILE CAPLUS (1907 TO DATE)

L2 ANSWER 6 OF 7 REGISTRY COPYRIGHT 2006 ACS on STN
RN 473308-00-8 REGISTRY
ED Entered STN: 12 Nov 2002
CN Benzenesulfonamide, 4-[3-(4-chlorophenyl)-5-methyl-4-isoxazolyl]-2,6-difluoro- (9CI) (CA INDEX NAME)
OTHER NAMES:
CN 2,6-Difluoro-4-[3-(4-chlorophenyl)-5-methylisoxazol-4-yl]benzenesulfonamide
FS 3D CONCORD
MF C16 H11 Cl F2 N2 O3 S
SR CA
LC STN Files: CA, CAPLUS, TOXCENTER, USPAT2, USPATFULL



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

1 REFERENCES IN FILE CA (1907 TO DATE)
1 REFERENCES IN FILE CAPLUS (1907 TO DATE)

L2 ANSWER 7 OF 7 REGISTRY COPYRIGHT 2006 ACS on STN
RN 219679-65-9 REGISTRY
ED Entered STN: 14 Feb 1999
CN Benzoic acid, 6-[4-[4-(aminosulfonyl)phenyl]-5-methyl-3-isoxazolyl]-2,3-dichloro- (9CI) (CA INDEX NAME)
FS 3D CONCORD
MF C17 H12 Cl2 N2 O5 S
SR CA
LC STN Files: CA, CAPLUS, USPATFULL



MMP-13 inhibitors

PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

1 REFERENCES IN FILE CA (1907 TO DATE)
1 REFERENCES IN FILE CAPLUS (1907 TO DATE)

=> FIL REGISTRY

COST IN U.S. DOLLARS	SINCE FILE ENTRY	TOTAL SESSION
FULL ESTIMATED COST	14.62	14.83

FILE 'REGISTRY' ENTERED AT 10:48:11 ON 30 MAR 2006

Property values tagged with IC are from the ZIC/VINITI data file provided by InfoChem.

STRUCTURE FILE UPDATES: 28 MAR 2006 HIGHEST RN 878378-71-3
DICTIONARY FILE UPDATES: 28 MAR 2006 HIGHEST RN 878378-71-3

New CAS Information Use Policies, enter HELP USAGETERMS for details.

TSCA INFORMATION NOW CURRENT THROUGH January 6, 2006

Please note that search-term pricing does apply when conducting SmartSELECT searches.

****
* *
* The CA roles and document type information have been removed from *
* the IDE default display format and the ED field has been added, *
* effective March 20, 2005. A new display format, IDERL, is now *
* available and contains the CA role and document type information. *
* *
****

Structure search iteration limits have been increased. See HELP SLIMITS for details.

REGISTRY includes numerically searchable data for experimental and predicted properties as well as tags indicating availability of experimental property data in the original document. For information on property searching in REGISTRY, refer to:

http://www.cas.org/ONLINE/UG/regprops.html

=> S 181695-72-7/RN

L3 1 181695-72-7/RN

=> SET NOTICE 1 DISPLAY

NOTICE SET TO 1 U.S. DOLLAR FOR DISPLAY COMMAND
SET COMMAND COMPLETED

=> D L3 SQIDE 1-

YOU HAVE REQUESTED DATA FROM 1 ANSWERS - CONTINUE? Y/(N):y
THE ESTIMATED COST FOR THIS REQUEST IS 6.36 U.S. DOLLARS

MMP-13 inhibitors

DO YOU WANT TO CONTINUE WITH THIS REQUEST? (Y)/N:y

L3 ANSWER 1 OF 1 REGISTRY COPYRIGHT 2006 ACS on STN
RN **181695-72-7** REGISTRY
CN Benzenesulfonamide, 4-(5-methyl-3-phenyl-4-isoxazolyl)- (9CI) (CA INDEX NAME)
OTHER NAMES:
CN 4-(5-Methyl-3-phenylisoxazol-4-yl)benzenesulfonamide
CN Bextra
CN SC 65872
CN Valdecoxib
CN Valecoxib
FS 3D CONCORD
MF C16 H14 N2 O3 S
CI COM
SR CA
LC STN Files: ADISINSIGHT, ANABSTR, BIOSIS, BIOTECHNO, CA, CAPLUS, CASREACT, CBNB, CHEMCATS, CSCHEM, EMBASE, HSDB*, IMSDRUGNEWS, IMSPATENTS, IMSRESEARCH, IPA, MRCK*, PATDPASPC, PHAR, PROUSDDR, PS, RTECS*, SYNTHLINE, TOXCENTER, USAN, USPAT2, USPATFULL
(*File contains numerically searchable property data)
DT.CA CAplus document type: Conference; Journal; Patent
RL.P Roles from patents: BIOL (Biological study); PREP (Preparation); PROC (Process); PRP (Properties); RACT (Reactant or reagent); USES (Uses)
RLD.P Roles for non-specific derivatives from patents: BIOL (Biological study); USES (Uses)
RL.NP Roles from non-patents: ANST (Analytical study); BIOL (Biological study); FORM (Formation, nonpreparative); PREP (Preparation); PROC (Process); PRP (Properties); RACT (Reactant or reagent); USES (Uses)
RLD.NP Roles for non-specific derivatives from non-patents: BIOL (Biological study); PREP (Preparation); PRP (Properties); USES (Uses)



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

534 REFERENCES IN FILE CA (1907 TO DATE)
23 REFERENCES TO NON-SPECIFIC DERIVATIVES IN FILE CA
538 REFERENCES IN FILE CAPLUS (1907 TO DATE)

=> SET NOTICE LOGIN DISPLAY

NOTICE SET TO OFF FOR DISPLAY COMMAND
SET COMMAND COMPLETED

=>

MMP-13 inhibitors

=> FIL REGISTRY

COST IN U.S. DOLLARS	SINCE FILE ENTRY	TOTAL SESSION
FULL ESTIMATED COST	2.34	17.17

FILE 'REGISTRY' ENTERED AT 10:48:38 ON 30 MAR 2006
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.

Property values tagged with IC are from the ZIC/VINITI data file
provided by InfoChem.

STRUCTURE FILE UPDATES: 28 MAR 2006 HIGHEST RN 878378-71-3
DICTIONARY FILE UPDATES: 28 MAR 2006 HIGHEST RN 878378-71-3

New CAS Information Use Policies, enter HELP USAGETERMS for details.

TSCA INFORMATION NOW CURRENT THROUGH January 6, 2006

Please note that search-term pricing does apply when
conducting SmartSELECT searches.

```
**********************************************************************
*                                                                    *
* The CA roles and document type information have been removed from *
* the IDE default display format and the ED field has been added,    *
* effective March 20, 2005.  A new display format, IDERL, is now     *
* available and contains the CA role and document type information.  *
*                                                                    *
**********************************************************************
```

Structure search iteration limits have been increased. See HELP SLIMITS
for details.

REGISTRY includes numerically searchable data for experimental and
predicted properties as well as tags indicating availability of
experimental property data in the original document. For information
on property searching in REGISTRY, refer to:

http://www.cas.org/ONLINE/UG/regprops.html

=> SET TERMSET E#

SET COMMAND COMPLETED

=> DEL SEL Y

=> SEL L3 1 RN

E1 THROUGH E1 ASSIGNED

=> S E1/RN

L4 1 181695-72-7/RN

=> SET TERMSET LOGIN

SET COMMAND COMPLETED

MMP-13 inhibitors

=> FIL USPATFULL

COST IN U.S. DOLLARS	SINCE FILE ENTRY	TOTAL SESSION
FULL ESTIMATED COST	0.52	17.69

FILE 'USPATFULL' ENTERED AT 10:48:43 ON 30 MAR 2006
CA INDEXING COPYRIGHT (C) 2006 AMERICAN CHEMICAL SOCIETY (ACS)

FILE COVERS 1971 TO PATENT PUBLICATION DATE: 30 Mar 2006 (20060330/PD)
FILE LAST UPDATED: 30 Mar 2006 (20060330/ED)
HIGHEST GRANTED PATENT NUMBER: US7020895
HIGHEST APPLICATION PUBLICATION NUMBER: US2006070159
CA INDEXING IS CURRENT THROUGH 28 Mar 2006 (20060328/UPCA)
ISSUE CLASS FIELDS (/INCL) CURRENT THROUGH: 30 Mar 2006 (20060330/PD)
REVISED CLASS FIELDS (/NCL) LAST RELOADED: Feb 2006
USPTO MANUAL OF CLASSIFICATIONS THESAURUS ISSUE DATE: Feb 2006

=> S L4

L5 311 L4

=> S L5 AND 1990<=PY<=2001 AND (PATENT)/DT AND (ENGLISH)/LA
1687978 1990<=PY<=2001
4417602 (PATENT)/DT
4417602 (ENGLISH)/LA
L6 12 L5 AND 1990<=PY<=2001 AND (PATENT)/DT AND (ENGLISH)/LA

=> DIS L6 1- TRIAL
YOU HAVE REQUESTED DATA FROM 12 ANSWERS - CONTINUE? Y/(N):Y

L6 ANSWER 1 OF 12 USPATFULL on STN
AN 2003:67775 USPATFULL
TI Method of treating neurodegenerative diseases
INCL INCLM: 514/315.000
INCLS: 514/408.000; 514/438.000; 514/461.000
NCL NCLM: 514/315.000
NCLS: 514/408.000; 514/438.000; 514/461.000
IC [7]
ICM A61K031-445
ICS A61K031-40; A61K031-38; A61K031-34
IPCI A61K0031-445 [ICM,7]; A61K0031-40 [ICS,7]; A61K0031-38 [ICS,7];
A61K0031-34 [ICS,7]
IPCR A61K0031-34 [I,A]; A61K0031-34 [I,C]; A61K0031-38 [I,A];
A61K0031-38 [I,C]; A61K0031-40 [I,A]; A61K0031-40 [I,C];
A61K0031-55 [I,A]; A61K0031-55 [I,C]
GI

SECTION	PAGES	FORMAT	SIZE
FRONT PAGE	1	PAGE.FP	38K
DESCRIPTION	2-5	PAGE.DESC	401K
CLAIMS	5-6	PAGE.CLM	134K
COMPLETE	1-6	PAGE.ALL	480K

Use PAGE(n) to retrieve a specific page

L6 ANSWER 2 OF 12 USPATFULL on STN
AN 2001:215073 USPATFULL
TI Treatment of heart disease with cox-2 inhibitors
INCL INCLM: 514/343.000
INCLS: 514/378.000; 514/403.000; 514/473.000
NCL NCLM: 514/343.000
NCLS: 514/378.000; 514/403.000; 514/473.000

MMP-13 inhibitors

IC [7]
ICM A61K031-44
ICS A61K031-42; A61K031-415; A61K031-34; A61P009-04
IPCI A61K0031-44 [ICM,7]; A61K0031-42 [ICS,7]; A61K0031-415 [ICS,7]; A61K0031-34 [ICS,7]; A61P0009-04 [ICS,7]
IPCR A61K0031-00 [I,A]; A61K0031-00 [I,C]; A61K0031-34 [I,A]; A61K0031-34 [I,C]; A61K0031-365 [I,A]; A61K0031-365 [I,C]; A61K0031-415 [I,A]; A61K0031-415 [I,C]; A61K0031-42 [I,A]; A61K0031-42 [I,C]; A61K0031-44 [I,A]; A61K0031-44 [I,C]; A61K0031-4427 [I,C]; A61K0031-444 [I,A]; A61K0045-00 [I,C]; A61K0045-06 [I,A]

PAGE IMAGES NOT AVAILABLE FOR THIS PATENT

L6 ANSWER 3 OF 12 USPATFULL on STN
AN 2001:205933 USPATFULL
TI Nitrosated and nitrosylated cyclooxygenase-2 inhibitors, compositions and methods of use
INCL INCLM: 514/361.000
INCLS: 548/127.000; 548/360.100; 548/250.000; 514/249.000
NCL NCLM: 514/326.000; 514/361.000
NCLS: 514/378.000; 514/406.000; 546/209.000; 548/247.000; 548/248.000; 548/375.100; 548/561.000; 514/249.000; 548/127.000; 548/250.000; 548/360.100
IC [7]
ICM A61K031-495
ICS A61K031-50; A01N043-58; A01N043-60; A61K031-41; A01N043-82
IPCI A61K0031-495 [ICM,7]; A61K0031-50 [ICS,7]; A01N0043-58 [ICS,7]; A01N0043-60 [ICS,7]; A61K0031-41 [ICS,7]; A01N0043-82 [ICS,7]
IPCI-2 C07D0207-325 [ICM,7]; C07D0231-06 [ICS,7]; A61K0031-40 [ICS,7]; A61K0031-415 [ICS,7]
IPCR C07C0317-00 [I,C]; C07C0317-46 [I,A]; C07C0381-00 [I,A]; C07C0381-00 [I,C]; C07D0207-00 [I,C]; C07D0207-333 [I,A]; C07D0209-00 [I,C]; C07D0209-12 [I,A]; C07D0209-18 [I,A]; C07D0231-00 [I,C]; C07D0231-12 [I,A]; C07D0231-14 [I,A]; C07D0233-00 [I,C]; C07D0233-54 [I,A]; C07D0237-00 [I,C]; C07D0237-14 [I,A]; C07D0261-00 [I,C]; C07D0261-08 [I,A]; C07D0263-00 [I,C]; C07D0263-20 [I,A]; C07D0311-00 [I,C]; C07D0311-12 [I,A]; C07D0413-00 [I,C]; C07D0413-12 [I,A]; C07D0471-00 [I,C]; C07D0471-04 [I,A]

PAGE IMAGES NOT AVAILABLE FOR THIS PATENT

L6 ANSWER 4 OF 12 USPATFULL on STN
AN 2001:185277 USPATFULL
TI Protected forms of a combination of pharmacologically active agents and uses therefor
INCL INCLM: 514/159.000
INCLS: 514/161.000; 514/569.000; 514/570.000; 514/567.000; 514/629.000; 514/158.000
NCL NCLM: 514/159.000
NCLS: 514/158.000; 514/161.000; 514/567.000; 514/569.000; 514/570.000; 514/629.000
IC [7]
ICM A01N037-36
ICS A01N043-00; A01N051-00; A01N037-10; A01N037-18
IPCI A01N0037-36 [ICM,7]; A01N0043-00 [ICS,7]; A01N0051-00 [ICS,7]; A01N0037-10 [ICS,7]; A01N0037-18 [ICS,7]
IPCR C07D0261-00 [I,C]; C07D0261-08 [I,A]

PAGE IMAGES NOT AVAILABLE FOR THIS PATENT

L6 ANSWER 5 OF 12 USPATFULL on STN
AN 2001:91602 USPATFULL
TI Crystalline form of 4- [5-methyl-3-phenylisoxazol-4-yl] benzenesulfonamide

MMP-13 inhibitors

INCL INCLM: 514/378.000
INCLS: 548/240.000
NCL NCLM: 514/378.000
NCLS: 548/247.000; 548/240.000
IC [7]
ICM A61K031-42
IPCI A61K0031-42 [ICM,7]
IPCI-2 A61K0031-42 [ICM,7]; C07D0261-08 [ICS,7]
IPCR C07D0261-00 [I,C]; C07D0261-08 [I,A]
PAGE IMAGES NOT AVAILABLE FOR THIS PATENT

L6 ANSWER 6 OF 12 USPATFULL on STN
AN 2001:4770 USPATFULL
TI Immunosuppressive effects of administration of a cyclooxygenase-2 inhibitor and a leukotriene B4 receptor antagonist
INCL INCLM: 514/395.000
INCLS: 514/406.000; 548/370.100; 548/377.100; 548/364.100; 548/365.700
NCL NCLM: 514/395.000
NCLS: 514/406.000; 548/364.100; 548/365.700; 548/370.100; 548/377.100
IC [7]
ICM A61K031-415
ICS C07D231-02; C07D231-12
IPCI A61K0031-415 [ICM,7]; C07D0231-02 [ICS,7]; C07D0231-12 [ICS,7]
IPCR A61K0038-12 [I,C]; A61K0038-13 [I,A]; A61K0045-00 [I,C]; A61K0045-06 [I,A]
PAGE IMAGES NOT AVAILABLE FOR THIS PATENT

L6 ANSWER 7 OF 12 USPATFULL on STN
AN 1999:146601 USPATFULL
TI Substituted isoxazole for the treatment of inflammation
INCL INCLM: 514/340.000
INCLS: 546/272.100
NCL NCLM: 514/340.000
NCLS: 546/272.100
IC [6]
ICM A61K031-44
ICS C07D413-04; C07D413-06; C07D413-12
IPCI A61K0031-44 [ICM,6]; C07D0413-04 [ICS,6]; C07D0413-06 [ICS,6]; C07D0413-12 [ICS,6]
IPCR C07D0261-00 [I,C]; C07D0261-08 [I,A]; C07D0261-10 [I,A]; C07D0261-12 [I,A]; C07D0261-18 [I,A]; C07D0413-00 [I,C]; C07D0413-04 [I,A]
PAGE IMAGES NOT AVAILABLE FOR THIS PATENT

L6 ANSWER 8 OF 12 USPATFULL on STN
AN 1999:89174 USPATFULL
TI Prodrugs of benzenesulfonamide-containing COX-2 inhibitors
INCL INCLM: 514/341.000
INCLS: 514/374.000; 514/397.000; 514/399.000; 514/403.000; 514/406.000; 514/602.000; 546/274.100; 546/290.000; 548/225.000; 548/228.000; 548/229.000; 548/314.700; 548/315.100; 548/235.000; 548/328.500; 548/335.500; 548/375.100; 548/376.100; 548/377.100; 548/359.500; 548/541.000; 548/544.000; 548/556.000; 564/061.000; 564/084.000
NCL NCLM: 514/341.000
NCLS: 514/374.000; 514/397.000; 514/399.000; 514/403.000; 514/406.000; 514/602.000; 546/274.100; 546/290.000; 548/225.000; 548/228.000; 548/229.000; 548/235.000; 548/314.700; 548/315.100; 548/328.500; 548/335.500; 548/359.500; 548/375.100; 548/376.100; 548/377.100; 548/541.000; 548/544.000; 548/556.000; 564/061.000; 564/084.000
IC [6]
ICM A61K031-42
ICS A61K031-415; A61K031-16; C07D211-72; C07D211-84; C07D263-32; C07D403-02; C07D223-04; C07D231-10; C07D207-00; C07D207-12

MMP-13 inhibitors

IPCI A61K0031-42 [ICM,6]; A61K0031-415 [ICS,6]; A61K0031-16 [ICS,6];
C07D0211-72 [ICS,6]; C07D0211-84 [ICS,6]; C07D0263-32 [ICS,6];
C07D0403-02 [ICS,6]; C07D0223-04 [ICS,6]; C07D0231-10 [ICS,6];
C07D0207-00 [ICS,6]; C07D0207-12 [ICS,6]
IPCR A61K0031-18 [I,A]; A61K0031-18 [I,C]; A61K0031-415 [I,A];
A61K0031-415 [I,C]; A61K0031-42 [I,A]; A61K0031-42 [I,C];
A61K0031-63 [I,C]; A61K0031-635 [I,A]; C07C0311-00 [I,C];
C07C0311-16 [I,A]; C07C0311-51 [I,A]; C07D0207-00 [I,C];
C07D0207-33 [I,A]; C07D0231-00 [I,C]; C07D0231-12 [I,A];
C07D0233-00 [I,C]; C07D0233-54 [I,A]; C07D0261-00 [I,C];
C07D0261-08 [I,A]; C07D0263-00 [I,C]; C07D0263-32 [I,A];
C07D0307-00 [I,C]; C07D0307-58 [I,A]; C07D0401-00 [I,C];
C07D0401-04 [I,A]; C07D0417-00 [I,C]; C07D0417-04 [I,A];
C07D0495-00 [I,C]; C07D0495-04 [I,A]
PAGE IMAGES NOT AVAILABLE FOR THIS PATENT

L6 ANSWER 9 OF 12 USPATFULL on STN
AN 1999:4908 USPATFULL
TI Isoxazole compounds as cyclooxygenase inhibitors
INCL INCLM: 548/247.000
INCLS: 546/272.100; 548/243.000; 548/245.000; 548/248.000
NCL NCLM: 548/247.000
NCLS: 546/272.100; 548/243.000; 548/245.000; 548/248.000
IC [6]
ICM C07D261-06
IPCI C07D0261-06 [ICM,6]
IPCR C07D0261-00 [I,C]; C07D0261-08 [I,A]; C07D0261-10 [I,A];
C07D0261-12 [I,A]; C07D0261-18 [I,A]; C07D0413-00 [I,C];
C07D0413-04 [I,A]
PAGE IMAGES NOT AVAILABLE FOR THIS PATENT

L6 ANSWER 10 OF 12 USPATFULL on STN
AN 97:120633 USPATFULL
TI Treatment of inflammation and inflammation-related disorders with a combination of a cyclooxygenase-2 inhibitor and a leukotriene A.sub.4 hydrolase inhibitor
INCL INCLM: 514/326.000
INCLS: 514/330.000; 514/317.000; 514/422.000; 514/445.000; 514/438.000;
514/559.000; 514/602.000; 514/603.000; 514/406.000; 514/407.000;
514/403.000; 514/404.000; 514/567.000; 514/381.000; 514/648.000
NCL NCLM: 514/326.000
NCLS: 514/317.000; 514/330.000; 514/381.000; 514/403.000; 514/404.000;
514/406.000; 514/407.000; 514/422.000; 514/438.000; 514/445.000;
514/559.000; 514/567.000; 514/602.000; 514/603.000; 514/648.000
IC [6]
ICM A61K031-445
ICS A61K031-40; A61K031-38; A61K031-20; A61K031-18; A61K031-415;
A61K031-195; A61K031-135
IPCI A61K0031-445 [ICM,6]; A61K0031-40 [ICS,6]; A61K0031-38 [ICS,6];
A61K0031-20 [ICS,6]; A61K0031-18 [ICS,6]; A61K0031-415 [ICS,6];
A61K0031-195 [ICS,6]; A61K0031-135 [ICS,6]
IPCR A61K0045-00 [I,C]; A61K0045-06 [I,A]
PAGE IMAGES NOT AVAILABLE FOR THIS PATENT

L6 ANSWER 11 OF 12 USPATFULL on STN
AN 97:56699 USPATFULL
TI Substituted sulfonylphenylheterocycles as cyclooxygenase-2 and 5-lipoxygenase inhibitors
INCL INCLM: 514/372.000
INCLS: 514/340.000; 514/369.000; 514/370.000; 514/365.000; 514/376.000;
514/377.000; 514/374.000; 514/378.000; 514/380.000; 546/271.400;
546/272.100; 548/225.000; 548/228.000; 548/229.000; 548/234.000;
548/235.000; 548/236.000; 548/243.000; 548/245.000; 548/246.000;

```
                548/247.000; 548/248.000
NCL     NCLM:   514/372.000
        NCLS:   514/340.000; 514/365.000; 514/369.000; 514/370.000; 514/374.000;
                514/376.000; 514/377.000; 514/378.000; 514/380.000; 546/271.400;
                546/272.100; 548/225.000; 548/228.000; 548/229.000; 548/234.000;
                548/235.000; 548/236.000; 548/243.000; 548/245.000; 548/246.000;
                548/247.000; 548/248.000
IC      [6]
        ICM     A61K031-44
        ICS     A61K031-425; A61K031-42; C09D263-32; C07D413-12; C07D413-06;
                C07D413-10; C07D417-02
        IPCI    A61K0031-44 [ICM,6]; A61K0031-425 [ICS,6]; A61K0031-42 [ICS,6];
                C09D0263-32 [ICS,6]; C07D0413-12 [ICS,6]; C07D0413-06 [ICS,6];
                C07D0413-10 [ICS,6]; C07D0417-02 [ICS,6]
        IPCR    C07D0231-00 [I,C]; C07D0231-12 [I,A]; C07D0405-00 [I,C];
                C07D0405-12 [I,A]; C07D0413-00 [I,C]; C07D0413-10 [I,A];
                C07D0413-12 [I,A]
PAGE IMAGES NOT AVAILABLE FOR THIS PATENT

L6    ANSWER 12 OF 12  USPATFULL on STN
AN      97:45034  USPATFULL
TI      Substituted isoxazoles for the treatment of inflammation
INCL    INCLM: 514/378.000
        INCLS: 548/182.000; 548/186.000; 548/190.000; 548/193.000; 548/202.000;
                548/203.000; 548/225.000; 548/228.000; 548/229.000; 548/232.000;
                548/234.000; 548/235.000; 548/243.000; 548/245.000; 548/247.000;
                548/248.000; 546/272.100; 544/405.000; 514/255.000; 514/340.000;
                514/365.000; 514/369.000; 514/370.000; 514/374.000; 514/376.000;
                514/377.000; 514/380.000
NCL     NCLM:   514/378.000
        NCLS:   514/254.040; 514/340.000; 514/365.000; 514/369.000; 544/405.000;
                546/272.100; 548/182.000; 548/186.000; 548/190.000; 548/193.000;
                548/202.000; 548/203.000; 548/225.000; 548/228.000; 548/229.000;
                548/232.000; 548/234.000; 548/235.000; 548/243.000; 548/245.000;
                548/247.000; 548/248.000
IC      [6]
        ICM     C07D261-06
        ICS     C07D261-10; C07D261-12; C07D261-14; A61K031-42
        IPCI    C07D0261-06 [ICM,6]; C07D0261-10 [ICS,6]; C07D0261-12 [ICS,6];
                C07D0261-14 [ICS,6]; A61K0031-42 [ICS,6]
        IPCR    C07D0261-00 [I,C]; C07D0261-08 [I,A]; C07D0261-10 [I,A];
                C07D0261-12 [I,A]; C07D0261-18 [I,A]; C07D0413-00 [I,C];
                C07D0413-04 [I,A]
PAGE IMAGES NOT AVAILABLE FOR THIS PATENT


=> logoff
ALL L# QUERIES AND ANSWER SETS ARE DELETED AT LOGOFF
LOGOFF? (Y)/N/HOLD:y
COST IN U.S. DOLLARS                            SINCE FILE      TOTAL
                                                   ENTRY    SESSION
FULL ESTIMATED COST                                 4.31      22.00

STN INTERNATIONAL LOGOFF AT 10:50:35 ON 30 MAR 2006
```

MMP-13 inhibitors

Connecting via Winsock to STN

Welcome to STN International! Enter x:x

LOGINID:SSPTAEXO1623

PASSWORD:
TERMINAL (ENTER 1, 2, 3, OR ?):2

* * * * * * * * * * Welcome to STN International * * * * * * * * * *

NEWS	1		Web Page URLs for STN Seminar Schedule - N. America
NEWS	2		"Ask CAS" for self-help around the clock
NEWS	3	DEC 21	IPC search and display fields enhanced in CA/CAplus with the IPC reform
NEWS	4	DEC 23	New IPC8 SEARCH, DISPLAY, and SELECT fields in USPATFULL/ USPAT2
NEWS	5	JAN 13	IPC 8 searching in IFIPAT, IFIUDB, and IFICDB
NEWS	6	JAN 13	New IPC 8 SEARCH, DISPLAY, and SELECT enhancements added to INPADOC
NEWS	7	JAN 17	Pre-1988 INPI data added to MARPAT
NEWS	8	JAN 17	IPC 8 in the WPI family of databases including WPIFV
NEWS	9	JAN 30	Saved answer limit increased
NEWS	10	JAN 31	Monthly current-awareness alert (SDI) frequency added to TULSA
NEWS	11	FEB 21	STN AnaVist, Version 1.1, lets you share your STN AnaVist visualization results
NEWS	12	FEB 22	Status of current WO (PCT) information on STN
NEWS	13	FEB 22	The IPC thesaurus added to additional patent databases on STN
NEWS	14	FEB 22	Updates in EPFULL; IPC 8 enhancements added
NEWS	15	FEB 27	New STN AnaVist pricing effective March 1, 2006
NEWS	16	FEB 28	MEDLINE/LMEDLINE reload improves functionality
NEWS	17	FEB 28	TOXCENTER reloaded with enhancements
NEWS	18	FEB 28	REGISTRY/ZREGISTRY enhanced with more experimental spectral property data
NEWS	19	MAR 01	INSPEC reloaded and enhanced
NEWS	20	MAR 03	Updates in PATDPA; addition of IPC 8 data without attributes
NEWS	21	MAR 08	X.25 communication option no longer available after June 2006
NEWS	22	MAR 22	EMBASE is now updated on a daily basis

NEWS EXPRESS FEBRUARY 15 CURRENT VERSION FOR WINDOWS IS V8.01a, CURRENT MACINTOSH VERSION IS V6.0c(ENG) AND V6.0Jc(JP), AND CURRENT DISCOVER FILE IS DATED 19 DECEMBER 2005. V8.0 AND V8.01 USERS CAN OBTAIN THE UPGRADE TO V8.01a AT http://download.cas.org/express/v8.0-Discover/

NEWS HOURS STN Operating Hours Plus Help Desk Availability
NEWS LOGIN Welcome Banner and News Items

Enter NEWS followed by the item number or name to see news on that specific topic.

MMP-13 inhibitors

```
  * * * * * * * * * * * * * * * STN  Columbus  * * * * * * * * * * * * * * * *

FILE 'HOME' ENTERED AT 11:29:30 ON 30 MAR 2006

=> file caplus uspatfull
COST IN U.S. DOLLARS                                    SINCE FILE      TOTAL
                                                           ENTRY    SESSION
FULL ESTIMATED COST                                         0.21       0.21

FILE 'CAPLUS' ENTERED AT 11:29:50 ON 30 MAR 2006
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.
COPYRIGHT (C) 2006 AMERICAN CHEMICAL SOCIETY (ACS)

FILE 'USPATFULL' ENTERED AT 11:29:50 ON 30 MAR 2006
CA INDEXING COPYRIGHT (C) 2006 AMERICAN CHEMICAL SOCIETY (ACS)

=> s MMP-13 or (matrix metalloprotease 13)
L1        1801 MMP-13 OR (MATRIX METALLOPROTEASE 13)

=> s L1 and arthritis
L2         898 L1 AND ARTHRITIS

=> dup rem
ENTER L# LIST OR (END):L2
PROCESSING COMPLETED FOR L2
L3          876 DUP REM L2 (22 DUPLICATES REMOVED)

=> s L3 and py<2002
L4         202 L3 AND PY<2002

=> d L4 1-20 ti

L4   ANSWER 1 OF 202  CAPLUS  COPYRIGHT 2006 ACS on STN
TI   Ricin-like toxin precursors cleavable by disease-specific proteinases for
     treatment of cancer, viral or parasitic infections

L4   ANSWER 2 OF 202  CAPLUS  COPYRIGHT 2006 ACS on STN
TI   Compositions and methods for systemic inhibition of cartilage degradation

L4   ANSWER 3 OF 202  CAPLUS  COPYRIGHT 2006 ACS on STN
TI   Preparation of sulfonyl aryl hydroxamates and their use as matrix
     metalloprotease inhibitors

L4   ANSWER 4 OF 202  CAPLUS  COPYRIGHT 2006 ACS on STN
TI   IL-1β-induced expression of matrix metalloproteinases and
     gliostatin/platelet-derived endothelial cell growth factor (GLS/PD-ECGF)
     in a chondrosarcoma cell line (OUMS-27)

L4   ANSWER 5 OF 202  CAPLUS  COPYRIGHT 2006 ACS on STN
TI   Production of cytokines, vascular endothelial growth factor, matrix
     metalloproteinases, and tissue inhibitor of metalloproteinases 1 by
     tenosynovium demonstrates its potential for tendon destruction in
     rheumatoid arthritis

L4   ANSWER 6 OF 202  CAPLUS  COPYRIGHT 2006 ACS on STN
TI   Design and synthesis of 4,4-disubstituted piperidine α-sulphone
     hydroxamates as potent and selective MMP inhibitors: The discovery of
     SC-77964

L4   ANSWER 7 OF 202  CAPLUS  COPYRIGHT 2006 ACS on STN
TI   Inhibition of tumor necrosis factor-α (TNF-α) production and
     arthritis in the rat by GW3333, a dual inhibitor of
```

MMP-13 inhibitors

TNF-α-converting enzyme and matrix metalloproteinases

L4 ANSWER 8 OF 202 CAPLUS COPYRIGHT 2006 ACS on STN
TI The potential of signal transduction inhibitors for the treatment of **arthritis**: is it all just JNK?

L4 ANSWER 9 OF 202 CAPLUS COPYRIGHT 2006 ACS on STN
TI Matrix metalloproteinase: Candidate for clinical joint destruction marker in arthropathy

L4 ANSWER 10 OF 202 CAPLUS COPYRIGHT 2006 ACS on STN
TI Analysis of the cell infiltrate and expression of matrix metalloproteinases and granzyme B in paired synovial biopsy specimens from the cartilage-pannus junction in patients with RA

L4 ANSWER 11 OF 202 CAPLUS COPYRIGHT 2006 ACS on STN
TI Tripterygium wilfordii Hook F extract suppresses proinflammatory cytokine-induced expression of matrix metalloproteinase genes in articular chondrocytes by inhibiting activating protein-1 and nuclear factor-κB activities

L4 ANSWER 12 OF 202 CAPLUS COPYRIGHT 2006 ACS on STN
TI Altered mRNA level of matrix metalloproteinase-13 in MH7A synovial cells under mechanical loading and unloading

L4 ANSWER 13 OF 202 CAPLUS COPYRIGHT 2006 ACS on STN
TI Preparation of acetylenic α-amino acid-based sulfonamide hydroxamic acid TACE inhibitors

L4 ANSWER 14 OF 202 CAPLUS COPYRIGHT 2006 ACS on STN
TI Messenger-RNA expression of matrix metalloproteinases, tissue inhibitors of metalloproteinases, and transcription factors in rheumatic synovial cells under mechanical stimuli

L4 ANSWER 15 OF 202 CAPLUS COPYRIGHT 2006 ACS on STN
TI Preparation of heteroaryl acetylenic sulfonamide and phosphinic acid amide hydroxamic acid TACE inhibitors

L4 ANSWER 16 OF 202 CAPLUS COPYRIGHT 2006 ACS on STN
TI Preparation of N-(p-benzyloxybenzenesulfonylamino)piperidine and -piperazine derivatives as selective inhibitors of aggrecanase in osteoarthritis treatment

L4 ANSWER 17 OF 202 CAPLUS COPYRIGHT 2006 ACS on STN
TI Oncostatin m-induced matrix metalloproteinase and tissue inhibitor of metalloproteinase-3 genes expression in chondrocytes requires janus kinase/STAT signaling pathway

L4 ANSWER 18 OF 202 CAPLUS COPYRIGHT 2006 ACS on STN
TI N-Hydroxy-2-(alkyl, aryl, or heteroaryl sulfanyl, sulfinyl, or sulfonyl)-3-substituted alkyl, aryl, or heteroaryl amides as matrix metalloproteinase inhibitors

L4 ANSWER 19 OF 202 CAPLUS COPYRIGHT 2006 ACS on STN
TI Interleukin 13 blocks the release of collagen from bovine nasal cartilage treated with proinflammatory cytokines

L4 ANSWER 20 OF 202 CAPLUS COPYRIGHT 2006 ACS on STN
TI N-Hydroxy-2-(alkyl, aryl or heteroaryl sulfanyl, sulfinyl or sulfonyl)-3-substituted alkyl, aryl or heteroaryl amides as matrix metalloproteinase inhibitors

MMP-13 inhibitors

=> s L4 and allosteric
L5 0 L4 AND ALLOSTERIC

=> s L4 and synthesis
L6 119 L4 AND SYNTHESIS

=> d L4 1-20 ti

L4 ANSWER 1 OF 202 CAPLUS COPYRIGHT 2006 ACS on STN
TI Ricin-like toxin precursors cleavable by disease-specific proteinases for treatment of cancer, viral or parasitic infections

L4 ANSWER 2 OF 202 CAPLUS COPYRIGHT 2006 ACS on STN
TI Compositions and methods for systemic inhibition of cartilage degradation

L4 ANSWER 3 OF 202 CAPLUS COPYRIGHT 2006 ACS on STN
TI Preparation of sulfonyl aryl hydroxamates and their use as matrix metalloprotease inhibitors

L4 ANSWER 4 OF 202 CAPLUS COPYRIGHT 2006 ACS on STN
TI IL-1β-induced expression of matrix metalloproteinases and gliostatin/platelet-derived endothelial cell growth factor (GLS/PD-ECGF) in a chondrosarcoma cell line (OUMS-27)

L4 ANSWER 5 OF 202 CAPLUS COPYRIGHT 2006 ACS on STN
TI Production of cytokines, vascular endothelial growth factor, matrix metalloproteinases, and tissue inhibitor of metalloproteinases 1 by tenosynovium demonstrates its potential for tendon destruction in rheumatoid **arthritis**

L4 ANSWER 6 OF 202 CAPLUS COPYRIGHT 2006 ACS on STN
TI Design and synthesis of 4,4-disubstituted piperidine α-sulphone hydroxamates as potent and selective MMP inhibitors: The discovery of SC-77964

L4 ANSWER 7 OF 202 CAPLUS COPYRIGHT 2006 ACS on STN
TI Inhibition of tumor necrosis factor-α (TNF-α) production and **arthritis** in the rat by GW3333, a dual inhibitor of TNF-α-converting enzyme and matrix metalloproteinases

L4 ANSWER 8 OF 202 CAPLUS COPYRIGHT 2006 ACS on STN
TI The potential of signal transduction inhibitors for the treatment of **arthritis**: is it all just JNK?

L4 ANSWER 9 OF 202 CAPLUS COPYRIGHT 2006 ACS on STN
TI Matrix metalloproteinase: Candidate for clinical joint destruction marker in arthropathy

L4 ANSWER 10 OF 202 CAPLUS COPYRIGHT 2006 ACS on STN
TI Analysis of the cell infiltrate and expression of matrix metalloproteinases and granzyme B in paired synovial biopsy specimens from the cartilage-pannus junction in patients with RA

L4 ANSWER 11 OF 202 CAPLUS COPYRIGHT 2006 ACS on STN
TI Tripterygium wilfordii Hook F extract suppresses proinflammatory cytokine-induced expression of matrix metalloproteinase genes in articular chondrocytes by inhibiting activating protein-1 and nuclear factor-κB activities

L4 ANSWER 12 OF 202 CAPLUS COPYRIGHT 2006 ACS on STN
TI Altered mRNA level of matrix metalloproteinase-13 in MH7A synovial cells under mechanical loading and unloading

MMP-13 inhibitors

L4 ANSWER 13 OF 202 CAPLUS COPYRIGHT 2006 ACS on STN
TI Preparation of acetylenic α-amino acid-based sulfonamide hydroxamic acid TACE inhibitors

L4 ANSWER 14 OF 202 CAPLUS COPYRIGHT 2006 ACS on STN
TI Messenger-RNA expression of matrix metalloproteinases, tissue inhibitors of metalloproteinases, and transcription factors in rheumatic synovial cells under mechanical stimuli

L4 ANSWER 15 OF 202 CAPLUS COPYRIGHT 2006 ACS on STN
TI Preparation of heteroaryl acetylenic sulfonamide and phosphinic acid amide hydroxamic acid TACE inhibitors

L4 ANSWER 16 OF 202 CAPLUS COPYRIGHT 2006 ACS on STN
TI Preparation of N-(p-benzyloxybenzenesulfonylamino)piperidine and -piperazine derivatives as selective inhibitors of aggrecanase in osteoarthritis treatment

L4 ANSWER 17 OF 202 CAPLUS COPYRIGHT 2006 ACS on STN
TI Oncostatin m-induced matrix metalloproteinase and tissue inhibitor of metalloproteinase-3 genes expression in chondrocytes requires janus kinase/STAT signaling pathway

L4 ANSWER 18 OF 202 CAPLUS COPYRIGHT 2006 ACS on STN
TI N-Hydroxy-2-(alkyl, aryl, or heteroaryl sulfanyl, sulfinyl, or sulfonyl)-3-substituted alkyl, aryl, or heteroaryl amides as matrix metalloproteinase inhibitors

L4 ANSWER 19 OF 202 CAPLUS COPYRIGHT 2006 ACS on STN
TI Interleukin 13 blocks the release of collagen from bovine nasal cartilage treated with proinflammatory cytokines

L4 ANSWER 20 OF 202 CAPLUS COPYRIGHT 2006 ACS on STN
TI N-Hydroxy-2-(alkyl, aryl or heteroaryl sulfanyl, sulfinyl or sulfonyl)-3-substituted alkyl, aryl or heteroaryl amides as matrix metalloproteinase inhibitors

=> s L4 not (tissue(w)inhibitor or TIMP)
L7 150 L4 NOT (TISSUE(W) INHIBITOR OR TIMP)

=> d L7 1-20 ti

L7 ANSWER 1 OF 150 CAPLUS COPYRIGHT 2006 ACS on STN
TI Ricin-like toxin precursors cleavable by disease-specific proteinases for treatment of cancer, viral or parasitic infections

L7 ANSWER 2 OF 150 CAPLUS COPYRIGHT 2006 ACS on STN
TI Compositions and methods for systemic inhibition of cartilage degradation

L7 ANSWER 3 OF 150 CAPLUS COPYRIGHT 2006 ACS on STN
TI Preparation of sulfonyl aryl hydroxamates and their use as matrix metalloprotease inhibitors

L7 ANSWER 4 OF 150 CAPLUS COPYRIGHT 2006 ACS on STN
TI IL-1β-induced expression of matrix metalloproteinases and gliostatin/platelet-derived endothelial cell growth factor (GLS/PD-ECGF) in a chondrosarcoma cell line (OUMS-27)

L7 ANSWER 5 OF 150 CAPLUS COPYRIGHT 2006 ACS on STN
TI Design and synthesis of 4,4-disubstituted piperidine α-sulphone hydroxamates as potent and selective MMP inhibitors: The discovery of SC-77964

MMP-13 inhibitors

L7 ANSWER 6 OF 150 CAPLUS COPYRIGHT 2006 ACS on STN
TI Inhibition of tumor necrosis factor-α (TNF-α) production and **arthritis** in the rat by GW3333, a dual inhibitor of TNF-α-converting enzyme and matrix metalloproteinases

L7 ANSWER 7 OF 150 CAPLUS COPYRIGHT 2006 ACS on STN
TI The potential of signal transduction inhibitors for the treatment of **arthritis**: is it all just JNK?

L7 ANSWER 8 OF 150 CAPLUS COPYRIGHT 2006 ACS on STN
TI Matrix metalloproteinase: Candidate for clinical joint destruction marker in arthropathy

L7 ANSWER 9 OF 150 CAPLUS COPYRIGHT 2006 ACS on STN
TI Analysis of the cell infiltrate and expression of matrix metalloproteinases and granzyme B in paired synovial biopsy specimens from the cartilage-pannus junction in patients with RA

L7 ANSWER 10 OF 150 CAPLUS COPYRIGHT 2006 ACS on STN
TI Tripterygium wilfordii Hook F extract suppresses proinflammatory cytokine-induced expression of matrix metalloproteinase genes in articular chondrocytes by inhibiting activating protein-1 and nuclear factor-κB activities

L7 ANSWER 11 OF 150 CAPLUS COPYRIGHT 2006 ACS on STN
TI Altered mRNA level of matrix metalloproteinase-13 in MH7A synovial cells under mechanical loading and unloading

L7 ANSWER 12 OF 150 CAPLUS COPYRIGHT 2006 ACS on STN
TI Preparation of acetylenic α-amino acid-based sulfonamide hydroxamic acid TACE inhibitors

L7 ANSWER 13 OF 150 CAPLUS COPYRIGHT 2006 ACS on STN
TI Preparation of heteroaryl acetylenic sulfonamide and phosphinic acid amide hydroxamic acid TACE inhibitors

L7 ANSWER 14 OF 150 CAPLUS COPYRIGHT 2006 ACS on STN
TI Preparation of N-(p-benzyloxybenzenesulfonylamino)piperidine and -piperazine derivatives as selective inhibitors of aggrecanase in osteoarthritis treatment

L7 ANSWER 15 OF 150 CAPLUS COPYRIGHT 2006 ACS on STN
TI N-Hydroxy-2-(alkyl, aryl, or heteroaryl sulfanyl, sulfinyl, or sulfonyl)-3-substituted alkyl, aryl, or heteroaryl amides as matrix metalloproteinase inhibitors

L7 ANSWER 16 OF 150 CAPLUS COPYRIGHT 2006 ACS on STN
TI N-Hydroxy-2-(alkyl, aryl or heteroaryl sulfanyl, sulfinyl or sulfonyl)-3-substituted alkyl, aryl or heteroaryl amides as matrix metalloproteinase inhibitors

L7 ANSWER 17 OF 150 CAPLUS COPYRIGHT 2006 ACS on STN
TI Cyclic sulphone MMP inhibitors

L7 ANSWER 18 OF 150 CAPLUS COPYRIGHT 2006 ACS on STN
TI Preparation of arylamido-substituted (hetero)cycloalkylacetamides as MMP and TNF-α inhibitors

L7 ANSWER 19 OF 150 CAPLUS COPYRIGHT 2006 ACS on STN
TI Preparation of acetylenic ortho-sulfonamido and phosphinic acid amido bicyclic heteroaryl hydroxamic acids as TACE inhibitors

MMP-13 inhibitors

L7 ANSWER 20 OF 150 CAPLUS COPYRIGHT 2006 ACS on STN
TI Preparation of heteroaryl acetylenic sulfonamide and phosphinic acid amide hydroxamic acid TACE inhibitors

=> d L7 2-3 ti abs bib

L7 ANSWER 2 OF 150 CAPLUS COPYRIGHT 2006 ACS on STN
TI Compositions and methods for systemic inhibition of cartilage degradation
AB Methods and compns. for inhibiting articular cartilage degradation are disclosed. The compns. preferably include multiple chondroprotective agents, including at least one agent that promotes cartilage anabolic activity and at least one agent that inhibits cartilage catabolism. The compns. may also include one or more pain and inflammation inhibitory agents. The compns. may be administered systemically, such as to treat patients at risk of cartilage degradation at multiple joints, and suitably may be formulated in a carrier or delivery vehicle that is targeted to the joints. Alternatively the compns. may be injected or infused directly into the joint.
AN 2003:1007594 CAPLUS
DN 140:47483
TI Compositions and methods for systemic inhibition of cartilage degradation
IN Demopulos, Gregory A.; Palmer, Pamela Pierce; Herz, Jeffrey M.
PA Omeros Corporation, USA
SO U.S. Pat. Appl. Publ., 71 pp., Cont.-in-part of U.S. Ser. No. 31,546.
CODEN: USXXCO
DT Patent
LA English
FAN.CNT 14

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	US 2003235589	A1	20031225	US 2003-356649	20030131
	AU 2000011277	A5	20000508	AU 2000-11277	19991020 <--
	EP 1261334	A1	20021204	EP 1999-955097	19991020
	R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, FI, CY				
	WO 2000025745	A2	20000511	WO 1999-US26330	19991105 <--
	WO 2000025745	A3	20000824		
	W: AE, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CR, CU, CZ, DE, DK, DM, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW				
	RW: GH, GM, KE, LS, MW, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG				
	WO 2001007067	A2	20010201	WO 2000-US19864	20000721 <--
	WO 2001007067	A3	20010329		
	W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CR, CU, CZ, DE, DK, DM, DZ, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW				
	RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG				
	US 2002028798	A1	20020307	US 2001-839633	20010420
PRAI	US 1998-105026P	P	19981020		
	US 1998-107256P	P	19981105		
	US 1999-144904P	P	19990721		
	WO 1999-US24625	A2	19991020		
	WO 1999-US26330	A2	19991105		

MMP-13 inhibitors

WO 2000-US19864	W	20000721
US 2001-839633	A2	20010420
US 2002-31546	A2	20020118
US 2002-353552P	P	20020201
US 1994-353775	B2	19941212
WO 1995-US16028	A2	19951212
US 1996-670699	A2	19960626
US 1998-72913	A2	19980504
US 1998-105029P	P	19981020
US 1998-105044P	P	19981020
US 1998-105166P	P	19981021
WO 1999-US24557	A2	19991020
WO 1999-US24558	A2	19991020
WO 1999-US24672	A2	19991020

L7 ANSWER 3 OF 150 CAPLUS COPYRIGHT 2006 ACS on STN
TI Preparation of sulfonyl aryl hydroxamates and their use as matrix metalloprotease inhibitors
GI



I



II

AB Title compds. I [W = 6-membered heterocycle containing the sulfonyl bonded N; A-R-E-Y = 4-substituent; A = O, SO0-2, etc.; R = alkyl, alkoxyalkyl, aryl, heteroaryl, cycloalkyl, etc.; E = absent , bond, CO, SO2, etc.; Y = absent, H, OH, CN, NO2, alkyl, haloalkyl, aminoalkyl; R5-6 = together with the atoms to which they are bonded, form an aliphatic or aromatic carbocyclic or heterocyclic ring having 5-7 members] are prepared Over 50 synthetic examples are disclosed. For example, phthalide is reacted with 4-(phenoxy)benzenethiol (DMF, K2CO3, 100°C, 2 h) and the resulting product converted to the hydroxamic acid (CH2Cl2, ClCOCOCl, DMF (cat), TMSONH2, 0°C, 1.5 h) followed by oxidation (CH2Cl2, mCPBA, room temperature, 3 h) to II. II has IC50 = 10 nM for MMP-2, 45 nM for **MMP-13** and >10,000 nM for MMP-1. I are inhibitors of MMP and angiogenesis.
AN 2003:300644 CAPLUS
DN 138:304308
TI Preparation of sulfonyl aryl hydroxamates and their use as matrix metalloprotease inhibitors

MMP-13 inhibitors

IN Barta, Thomas E.; Becker, Daniel P.; Bedell, Louis J.; Decrescenzo, Gary A.; Freskos, John N.; Getman, Daniel P.; McDonald, Joseph J.; Mischke, Brent V.; Rao, Shashidhar N.; Villamil, Clara I.
PA Pharmacia Corp., USA
SO U.S. Pat. Appl. Publ., 148 pp., Cont.-in-part of U.S. Ser. No. 569,034.
CODEN: USXXCO
DT Patent
LA English
FAN.CNT 10

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	US 2003073845	A1	20030417	US 2001-909227	20010719
	US 6696449	B2	20040224		
	WO 9838859	A1	19980911	WO 1998-US4300	19980304 <--
	W: AL, AU, BA, BB, BG, BR, CA, CN, CU, CZ, EE, GE, GH, GW, HU, ID, IL, IS, JP, KP, KR, LC, LK, LR, LT, LV, MG, MK, MN, MX, NO, NZ, PL, RO, SG, SI, SK, SL, TR, TT, UA, US, UZ, VN, YU, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
	RW: GH, GM, KE, LS, MW, SD, SZ, UG, ZW, AT, BE, CH, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, ML, MR, NE, SN, TD, TG				
	US 2001020021	A1	20010906	US 1999-230209	19990624 <--
	US 6380258	B2	20020430		
	US 2003191317	A1	20031009	US 2000-728408	20001201
	US 6794511	B2	20040921		
	CA 2453613	AA	20030130	CA 2002-2453613	20020719
	WO 2003007954	A2	20030130	WO 2002-US23219	20020719
	WO 2003007954	A3	20031023		
	W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZM, ZW				
	RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
	EP 1406626	A2	20040414	EP 2002-761148	20020719
	R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, SK				
	BR 2002011430	A	20040713	BR 2002-11430	20020719
	JP 2005502632	T2	20050127	JP 2003-513561	20020719
PRAI	US 1997-35182P	P	19970304		
	WO 1998-US4300	W	19980304		
	US 1999-310813	B1	19990512		
	US 1999-310813	B2	19990512		
	US 1999-230209	A2	19990624		
	US 2000-569034	A2	20000511		
	US 2000-728408	A2	20001201		
	US 2001-909227	A	20010719		
	WO 2002-US23219	W	20020719		

OS MARPAT 138:304308

=> file uspatfull

COST IN U.S. DOLLARS	SINCE FILE ENTRY	TOTAL SESSION
FULL ESTIMATED COST	57.67	57.88
DISCOUNT AMOUNTS (FOR QUALIFYING ACCOUNTS)	SINCE FILE ENTRY	TOTAL SESSION
CA SUBSCRIBER PRICE	-1.50	-1.50

MMP-13 inhibitors

FILE 'USPATFULL' ENTERED AT 11:35:20 ON 30 MAR 2006
CA INDEXING COPYRIGHT (C) 2006 AMERICAN CHEMICAL SOCIETY (ACS)

FILE COVERS 1971 TO PATENT PUBLICATION DATE: 30 Mar 2006 (20060330/PD)
FILE LAST UPDATED: 30 Mar 2006 (20060330/ED)
HIGHEST GRANTED PATENT NUMBER: US7020895
HIGHEST APPLICATION PUBLICATION NUMBER: US2006070159
CA INDEXING IS CURRENT THROUGH 28 Mar 2006 (20060328/UPCA)
ISSUE CLASS FIELDS (/INCL) CURRENT THROUGH: 30 Mar 2006 (20060330/PD)
REVISED CLASS FIELDS (/NCL) LAST RELOADED: Feb 2006
USPTO MANUAL OF CLASSIFICATIONS THESAURUS ISSUE DATE: Feb 2006

```
=> s MMP-13 or (matrix metalloprotease 13)
          4748 MMP
       3249028 13
           797 MMP-13
                 (MMP(W)13)
        402597 MATRIX
          2958 METALLOPROTEASE
       3249028 13
            28 MATRIX METALLOPROTEASE 13
                 (MATRIX(W)METALLOPROTEASE(W)13)
L8          798 MMP-13 OR (MATRIX METALLOPROTEASE 13)

=> s L8 and arthritis and py<2002
         47782 ARTHRITIS
       3023199 PY<2002
L9          136 L8 AND ARTHRITIS AND PY<2002

=> s L9 not (tissue(w)inhibitor or TIMP)
        278935 TISSUE
        137772 INHIBITOR
          2154 TISSUE(W)INHIBITOR
          2226 TIMP
L10          94 L9 NOT (TISSUE(W)INHIBITOR OR TIMP)

=> d L10 1-20 free
'FREE' IS NOT A VALID FORMAT FOR FILE 'USPATFULL'

The following are valid formats:

The default display format is STD.

ABS -------- AB
ALL -------- AN, TI, IN, INA, PA, PAA, PAT, PI, AI, PTERM, DCD,
             RLI, PRAI, DT, FS, REP, REN, EXNAM, LREP, CLMN, ECL,
             DRWN, AB, GOVI, PARN, SUMM, DRWD, DETD, CLM, INCL,
             INCLM, INCLS, NCL, NCLM, NCLS, IC, IPCI,
             IPCI-2, IPCR, EXF, ARTU
ALLG ------- ALL plus PAGE.DRAW
BIB -------- AN, TI, IN, INA, PA, PAA, PAT, PI, AI, PTERM, DCD, RLI,
             PRAI, DT, FS, EXNAM, LREP, CLMN, ECL, DRWN, LN.CNT
BIB.EX ----- BIB for original and latest publication
BIBG ------- BIB plus PAGE.DRAW
BROWSE ----- See "HELP BROWSE" or "HELP DISPLAY BROWSE".  BROWSE must
             entered on the same line as DISPLAY, e.g., D BROWSE.
CAS -------- OS, CC, SX, ST, IT
CBIB ------- AN, TI, IN, INA, PA, PAA, PAT, PI, AI, PRAI, DT, FS
DALL ------- ALL, delimited for post-processing
FP --------- PI, TI, IN, INA, PA, PAA, PAT, PTERM, DCD, AI, RLI,
             PRAI, IC, IPCI, IPCI-2, IPCR, INCL, INCLM, INCLS, NCL,
```

MMP-13 inhibitors

```
             NCLM, NCLS, EXF, REP, REN, ARTU, EXNAM, LREP,
             CLMN, DRWN, AB
FP.EX ------ FP for original and latest publication
FPALL ------ PI, TI, IN, INA, PA, PAA, PAT, PETRM, DCD, AI,
             RLI, PRAI, IC, IPCI, IPCI-2, IPCR, INCL, INCLM, INCLS, NCL, NCLM,
             NCLS, EXF, REP, REN, ARTU, EXNAM, LREP, CLMN, DRWN, AB,
             PARN, SUMM, DRWD, DETD, CLM
FPBIB ------ PI, TI, IN, INA, PA, PAA, PAT, PTERM, DCD, AI,
             RLI, PRAI, REP, REN, EXNAM, LREP, CLM, CLMN, DRWN
FHITSTR ---- HIT RN, its text modification, its CA index name, and
             its structure diagram
FPG -------- FP plus PAGE.DRAW
GI --------- PN and page image numbers
HIT -------- All fields containing hit terms
HITRN ------ HIT RN and its text modification
HITSTR ----- HIT RN, its text modification, its CA index name, and
             its structure diagram
IABS ------- ABS, indented with text labels
IALL ------- ALL, indented with text labels
IALLG ------ IALL plus PAGE.DRAW
IBIB ------- BIB, indented with text labels
IBIB.EX ---- IBIB for original and latest publication
IBIBG ------ IBIB plus PAGE.DRAW
IMAX ------- MAX, indented with text labels
IMAX.EX ---- IMAX for original and latest publication
IND -------- INCL, INCLM, INCLS, NCL, NCLM, NCLS, IC, IPCI, IPCI-2, IPCR,
             EXF, ARTU, OS, CC, SX, ST, IT
IPC.TAB ---- IPC in tabular format
ISTD ------- STD, indented with text labels
KWIC ------- All hit terms plus 20 words on either side
MAX -------- AN, TI, IN, INA, PA, PAA, PAT, PI, AI, PTERM, DCD,
             RLI, PRAI, DT, FS, REP, REN, EXNAM, LREP, CLMN, ECL,
             DRWN, AB, GOVI, PARN, SUMM, DRWD, DETD, CLM, INCL,
             INCLM, INCLS, NCL, NCLM, NCLS, IC, IPCI, IPCI-2,
             IPCR, EXF, ARTU OS, CC, SX, ST, IT
MAX.EX ----- MAX for original and latest publication
OCC -------- List of display fields containing hit terms
SBIB ------- AN, TI, IN, INA, PA, PAA, PAT, PI, AI, RLI, PRAI,
             DT, FS, LN.CNT
STD -------- AN, TI, IN, INA, PA, PAA, PAT, PI, AI, RLI, PRAI,
             DT, FS, LN.CNT, INCL, INCLM, INCLS, NCL, NCLM, NCLS,
             IC, IPCI, IPCI-2, IPCR, EXF (STD is the default)
STD.EX ----- STD for original and latest publication
TRIAL ------ AN, TI, INCL, INCLM, INCLS, NCL, NCLM, NCLS, IC,
             IPCI, IPCI-2, IPCR

SCAN ------- AN, TI, NCL, NCLM, NCLS, IC, IPCI, IPCI-2, IPCR(random display
             without answer number.  SCAN must be entered on the
             same line as DISPLAY, e.g., D SCAN)
ENTER DISPLAY FORMAT (STD):ti

L10  ANSWER 1 OF 94  USPATFULL on STN
TI     Benzimidazole derivatives useful as antiproliferative agents

L10  ANSWER 2 OF 94  USPATFULL on STN
TI     Use of immunosuppressants for MMP mediated diseases

L10  ANSWER 3 OF 94  USPATFULL on STN
TI     3-Arylsulfonyl-2 (substituted methyl) propanoic acid derivatives as
       matrix metalloproteinase inhibitors

L10  ANSWER 4 OF 94  USPATFULL on STN
TI     Phosphinic pseudo-peptides that may be used as matrix zinc
```

MMP-13 inhibitors

metalloprotease inhibitors

L10 ANSWER 5 OF 94 USPATFULL on STN
TI 2,3-substituted indole compounds as anti-inflammatory and analgesic agents

L10 ANSWER 6 OF 94 USPATFULL on STN
TI Carboxylic and hydroxamic acid compounds inhibiting metalloproteases, method for preparing same and pharmaceutical compositions containing them

L10 ANSWER 7 OF 94 USPATFULL on STN
TI Ricin-like toxin variants for treatment of cancer, viral or parasitic infections

L10 ANSWER 8 OF 94 USPATFULL on STN
TI N-hydroxacylamino compounds, process for their preparation and pharmaceutical compositions containing them

L10 ANSWER 9 OF 94 USPATFULL on STN
TI Aromatic sulfone hydroxamic acid metalloprotease inhibitor

L10 ANSWER 10 OF 94 USPATFULL on STN
TI Hydroxamic acid derivatives as matrix metalloprotease (MMP) inhibitors

L10 ANSWER 11 OF 94 USPATFULL on STN
TI Hydroxamic acid derivatives as proteinase inhibitors

L10 ANSWER 12 OF 94 USPATFULL on STN
TI Thiol compounds, their production and use

L10 ANSWER 13 OF 94 USPATFULL on STN
TI Hydroxamic acid derivatives as matrix metalloprotease (MMP) inhibitors

L10 ANSWER 14 OF 94 USPATFULL on STN
TI Acetylenic aryl sulfonamide and phosphinic acid amide hydroxamic acid TACE inhibitors

L10 ANSWER 15 OF 94 USPATFULL on STN
TI Piperazine compounds as inhibitors of MMP or TNF

L10 ANSWER 16 OF 94 USPATFULL on STN
TI N-Hydroxy-2-(Alkyl, Aryl, or Heteroaryl, Sulfanyl, Sulfinyl or Sulfonyl)-3-Substituted Alkyl, Aryl or Heteroarylamides as Matrix Metalloproteinase inhibitors

L10 ANSWER 17 OF 94 USPATFULL on STN
TI Preparation and use of ortho-sulfonamido heteroaryl hydroxamic acids as matrix metalloproteinase and TACE inhibitors

L10 ANSWER 18 OF 94 USPATFULL on STN
TI Formamide compounds as therapeutic agents

L10 ANSWER 19 OF 94 USPATFULL on STN
TI Hydroxy pipecolate hydroxamic acid derivatives

L10 ANSWER 20 OF 94 USPATFULL on STN
TI Acetylenic β-sulfonamido and phosphinic acid amide hydroxamic acid TACE inhibitors

=> d L10 3 5 15-17 ti bib

MMP-13 inhibitors

L10 ANSWER 3 OF 94 USPATFULL on STN
TI 3-Arylsulfonyl-2 (substituted methyl) propanoic acid derivatives as matrix metalloproteinase inhibitors
AN 2004:181063 USPATFULL
TI 3-Arylsulfonyl-2 (substituted methyl) propanoic acid derivatives as matrix metalloproteinase inhibitors
IN Mantegani, Sergio, Milan, ITALY
Abrate, Francesca, Milan, ITALY
Bissolino, Pierluigi, Pavia, ITALY
Cremonesi, Paolo, Milan, ITALY
Perrone, Ettore, Milan, ITALY
Jabes, Daniela, Milan, ITALY
PA Pharmacia Italia, SpA, Milan, ITALY (non-U.S. corporation)
PI US 6765003 B1 20040720
WO 2001005756 20010125 <--
AI US 2002-30681 20020409 (10)
WO 2000-EP6429 20000707
PRAI GB 1999-16562 19990714
DT Utility
FS GRANTED
EXNAM Primary Examiner: Raymond, Richard L.; Assistant Examiner: Patel, Sudhaker B.
LREP Akin Gump Strauss Hauer & Feld LLP, Mason, Dwayne L.
CLMN Number of Claims: 13
ECL Exemplary Claim: 1
DRWN 0 Drawing Figure(s); 0 Drawing Page(s)
LN.CNT 1787
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L10 ANSWER 5 OF 94 USPATFULL on STN
TI 2,3-substituted indole compounds as anti-inflammatory and analgesic agents
AN 2003:222110 USPATFULL
TI 2,3-substituted indole compounds as anti-inflammatory and analgesic agents
IN Nakao, Kazunari, 29-1, Sinbayashi, Shinbayahi-cho, Chiryu-shi, Aichi-ken, JAPAN 472-0017
Stevens, Rodney William, 3-4-26, Seoshiro-cho, Handa-shi, Aichi-ken, JAPAN 484-0081
Kawamura, Kiyoshi, 40-1, Daimonsaki, Inuyama, Inuyama-shi, Aichi-ken, JAPAN 484-0081
Uchida, Chikara, 118-401, Miyaji-cho, Handa-shi, Aichi-ken, JAPAN 475-0902
Koike, Hiroki, 1-100 Souga-cho, Handa-shi, Aichi-ken, JAPAN 475-0801
Caron, Stephane, 600 Meridian St. Extension-Apt. 509, Groton, CT, United States 06340
PI US 6608070 B1 20030819
WO 9935130 19990715 <--
AI US 1999-355494 19990728 (9)
WO 1998-IB2065 19981218
DT Utility
FS GRANTED
EXNAM Primary Examiner: Seaman, D. Margaret
LREP Richardson, Peter C., Ginsburg, Paul H., Catania, Richard L.
CLMN Number of Claims: 14
ECL Exemplary Claim: 1
DRWN 0 Drawing Figure(s); 0 Drawing Page(s)
LN.CNT 10227
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L10 ANSWER 15 OF 94 USPATFULL on STN
TI Piperazine compounds as inhibitors of MMP or TNF
AN 2001:235249 USPATFULL

MMP-13 inhibitors

TI Piperazine compounds as inhibitors of MMP or TNF
IN Neya, Masahiro, Tsuchiura, Japan
Yamazaki, Hitoshi, Tsukuba, Japan
Kayakiri, Natsuko, Suita, Japan
Sato, Kentaro, Tsukuba, Japan
Oku, Teruo, Takatsuki, Japan
PA Fujisawa Pharmaceutical Co., Ltd., Osaka, Japan (non-U.S. corporation)
PI US 6333324 B1 20011225 <--
WO 9827069 19980625 <--
AI US 1999-319928 19990726 (9)
WO 1997-JP4613 19971215
19990726 PCT 371 date
19990726 PCT 102(e) date
PRAI AU 1996-4249 19961217
AU 1997-7156 19970603
AU 1997-8568 19970814
DT Utility
FS GRANTED
EXNAM Primary Examiner: Shah, Mukund J.; Assistant Examiner: Liu, Hong
LREP Oblon, Spivak, McClelland, Maier & Neustadt, P.C.
CLMN Number of Claims: 9
ECL Exemplary Claim: 1
DRWN No Drawings
LN.CNT 5901
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L10 ANSWER 16 OF 94 USPATFULL on STN
TI N-Hydroxy-2-(Alkyl, Aryl, or Heteroaryl, Sulfanyl, Sulfinyl or Sulfonyl)-3-Substituted Alkyl, Aryl or Heteroarylamides as Matrix Metalloproteinase inhibitors
AN 2001:231300 USPATFULL
TI N-Hydroxy-2-(Alkyl, Aryl, or Heteroaryl, Sulfanyl, Sulfinyl or Sulfonyl)-3-Substituted Alkyl, Aryl or Heteroarylamides as Matrix Metalloproteinase inhibitors
IN Venkatesan, Aranapakam Mudumbai, 97-07 63rd Rd., #9K, Rego Park, NY, United States 11374
Grosu, George Theodore, 117 Prospect Pl., Pearl River, NY, United States 10965
Baker, Jannie Lea, 127 Rockinchair Rd., White Plains, NY, United States 10607
PI US 6331563 B1 20011218 <--
AI US 2000-587560 20000605 (9)
RLI Division of Ser. No. US 1998-140504, filed on 26 Aug 1998, now patented, Pat. No. US 6197791 Continuation-in-part of Ser. No. US 1998-26372, filed on 19 Feb 1998, now abandoned
PRAI US 1997-38899P 19970227 (60)
DT Utility
FS GRANTED
EXNAM Primary Examiner: Aulakh, Charanjit S.
LREP Hogan, Jr., John W.
CLMN Number of Claims: 9
ECL Exemplary Claim: 1
DRWN No Drawings
LN.CNT 6776
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L10 ANSWER 17 OF 94 USPATFULL on STN
TI Preparation and use of ortho-sulfonamido heteroaryl hydroxamic acids as matrix metalloproteinase and TACE inhibitors
AN 2001:229661 USPATFULL
TI Preparation and use of ortho-sulfonamido heteroaryl hydroxamic acids as matrix metalloproteinase and TACE inhibitors
IN Levin, Jeremy Ian, Nanuet, NY, United States

MMP-13 inhibitors

Nelson, Frances Christy, Wyckoff, NJ, United States
PI US 2001051614 A1 20011213 <--
AI US 2000-725707 A1 20001129 (9)
RLI Continuation of Ser. No. US 1999-330717, filed on 11 Jun 1999, GRANTED, Pat. No. US 6197795 Division of Ser. No. US 1997-944400, filed on 6 Oct 1997, GRANTED, Pat. No. US 5962481
PRAI US 1996-28969P 19961016 (60)
DT Utility
FS APPLICATION
LREP AMERICAN HOME PRODUCTS CORPORATION, PATENT SECTION, FIVE GIRALDA FARMS, MADISON, NJ, 07940-0874
CLMN Number of Claims: 11
ECL Exemplary Claim: 1
DRWN No Drawings
LN.CNT 1089
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

=> d L10 21-40 ti

L10 ANSWER 21 OF 94 USPATFULL on STN
TI Preparation and use of ortho-sulfonamido bicyclic heteroaryl hydroxamic acids as matrix metalloproteinase and TACE inhibitors

L10 ANSWER 22 OF 94 USPATFULL on STN
TI 2-oxo-imidazolidine-4-carboxylic acid hydroxamide compounds that inhibit matrix metalloproteinases

L10 ANSWER 23 OF 94 USPATFULL on STN
TI AROMATIC SULFONE HYDROXAMIC ACID METALLOPROTEASE INHIBITOR

L10 ANSWER 24 OF 94 USPATFULL on STN
TI Acetylenic sulfonamide thiol tace inhibitors

L10 ANSWER 25 OF 94 USPATFULL on STN
TI Metalloproteinase inhibitors, pharmaceutical compositions containing them, and their use

L10 ANSWER 26 OF 94 USPATFULL on STN
TI Arylsulfonylamino hydroxamic acid derivatives

L10 ANSWER 27 OF 94 USPATFULL on STN
TI Bicycliccarbonyl indole compounds as anti-inflammatory/analgesic agents

L10 ANSWER 28 OF 94 USPATFULL on STN
TI Preparation and use of ortho-sulfonamido bicyclic heteroaryl hydroxamic acids as matrix metalloproteinase and tace inhibitors

L10 ANSWER 29 OF 94 USPATFULL on STN
TI Sulfonylbenzene compounds as anti-inflammatory/analgesic agents

L10 ANSWER 30 OF 94 USPATFULL on STN
TI Heterocyclic hydroxamic acid derivatives as MMP inhibitors

L10 ANSWER 31 OF 94 USPATFULL on STN
TI Procollagen C-proteinase inhibitors

L10 ANSWER 32 OF 94 USPATFULL on STN
TI N-hydroxy-2-(alkyl, aryl, or heteroaryl, sulfanyl, sulfinyl or sulfonyl)-3-substituted alkyl, aryl or heteroarylamides as matrix metalloproteinase inhibitors

L10 ANSWER 33 OF 94 USPATFULL on STN

MMP-13 inhibitors

TI Diagnostic method for detection of periodontitis or peri-implantitis

L10 ANSWER 34 OF 94 USPATFULL on STN
TI Acetylenic aryl sulfonamide and phosphinic acid amide hydroxamic acid TACE inhibitors

L10 ANSWER 35 OF 94 USPATFULL on STN
TI Substituted indole compounds as anti-inflammatory and analgesic agents

L10 ANSWER 36 OF 94 USPATFULL on STN
TI AROMATIC SULFONE HYDROXAMIC ACID METALLOPROTEASE INHIBITOR

L10 ANSWER 37 OF 94 USPATFULL on STN
TI Process for preparing phenoxyphenylsulfonyl halides

L10 ANSWER 38 OF 94 USPATFULL on STN
TI Aryloxy-alkyl-dialkylamines

L10 ANSWER 39 OF 94 USPATFULL on STN
TI Human neutrophil collagenase splice variant

L10 ANSWER 40 OF 94 USPATFULL on STN
TI Aryloxy-alkyl-dialkylamines

=> d L10 21-40 ti bib

L10 ANSWER 21 OF 94 USPATFULL on STN
TI Preparation and use of ortho-sulfonamido bicyclic heteroaryl hydroxamic acids as matrix metalloproteinase and TACE inhibitors
AN 2001:218499 USPATFULL
TI Preparation and use of ortho-sulfonamido bicyclic heteroaryl hydroxamic acids as matrix metalloproteinase and TACE inhibitors
IN Levin, Jeremy I., Nanuet, NY, United States
Zask, Arie, New York, NY, United States
Gu, Yansong, Pearl River, NY, United States
Albright, Jay D., Nanuet, NY, United States
Du, Xuemei, Valley Cottage, NY, United States
PI US 2001046989 A1 20011129 <--
US 6548524 B2 20030415
AI US 2000-734140 A1 20001211 (9)
RLI Continuation-in-part of Ser. No. US 1997-944188, filed on 6 Oct 1997, ABANDONED
PRAI US 1996-28505P 19961016 (60)
DT Utility
FS APPLICATION
LREP BARRETT, REBECCA RALPH, WYETH AYERST, P.O. BOX 8299, PHILADELPHIA, PA, 19101
CLMN Number of Claims: 12
ECL Exemplary Claim: 1
DRWN No Drawings
LN.CNT 2535
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L10 ANSWER 22 OF 94 USPATFULL on STN
TI 2-oxo-imidazolidine-4-carboxylic acid hydroxamide compounds that inhibit matrix metalloproteinases
AN 2001:205917 USPATFULL
TI 2-oxo-imidazolidine-4-carboxylic acid hydroxamide compounds that inhibit matrix metalloproteinases
IN Robinson, Ralph P., Gales Ferry, CT, United States
Laird, Ellen R., Mystic, CT, United States
PI US 2001041710 A1 20011115 <--

MMP-13 inhibitors

```
       US 6458822          B2   20021001
AI     US 2000-730302      A1   20001205 (9)
PRAI   US 2000-188892P      20000313 (60)
DT     Utility
FS     APPLICATION
LREP   Paul H. Ginsburg, Pfizer Inc, 20th Floor, 235 East 42nd Street, New
       York, NY, 10017-5755
CLMN   Number of Claims: 28
ECL    Exemplary Claim: 1
DRWN   No Drawings
LN.CNT 1685
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L10  ANSWER 23 OF 94  USPATFULL on STN
TI     AROMATIC SULFONE HYDROXAMIC ACID METALLOPROTEASE INHIBITOR
AN     2001:200180  USPATFULL
TI     AROMATIC SULFONE HYDROXAMIC ACID METALLOPROTEASE INHIBITOR
IN     BARTA, THOMAS E, EVANSTON, IL, United States
       BECKER, DANIEL P, GLENVIEW, IL, United States
       BOEHM, TERRI L, BALLWIN, MO, United States
       DECRESCENZO, GARY A, ST CHARLES, MO, United States
       WILLAMI1, CLARA I, GLENVIEW, IL, United States
       MCDONALD, JOSEPH J, BALLWIN, MO, United States
       FRESKOS, JOHN N, CLAYTON, MO, United States
       GETMAN, DANIEL P, CHESTERFIELD, MO, United States
       HANSON, GUNNAR J, SKOKIE, IL, United States
PI     US 2001039287       A1   20011108                                <--
AI     US 1999-256948      A1   19990224 (9)
PRAI   US 1997-66007P       19971114 (60)
       US 1998-95347P       19980804 (60)
       US 1998-95501P       19980806 (60)
       US 1998-101080P      19980918 (60)
DT     Utility
FS     APPLICATION
LREP   WELSH & KATZ, 120 SOUTH RIVERSIDE PLAZA, 22ND FLOOR, CHICAGO, IL,
       606063913
CLMN   Number of Claims: 146
ECL    Exemplary Claim: 1
DRWN   No Drawings
LN.CNT 16461
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L10  ANSWER 24 OF 94  USPATFULL on STN
TI     Acetylenic sulfonamide thiol tace inhibitors
AN     2001:197020  USPATFULL
TI     Acetylenic sulfonamide thiol tace inhibitors
IN     Levin, Jeremy I., New City, NY, United States
       Chen, James M., Stoddard Court, NJ, United States
PA     American Cyanamid Company, Madison, NJ, United States (U.S. corporation)
PI     US 6313123          B1   20011106                                <--
AI     US 2000-492974           20000127 (9)
PRAI   US 1999-155218P     19990127 (60)
DT     Utility
FS     GRANTED
EXNAM  Primary Examiner: Ramsuer, Robert W.
LREP   Hogan, Jr., John W.
CLMN   Number of Claims: 13
ECL    Exemplary Claim: 1
DRWN   No Drawings
LN.CNT 1035
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L10  ANSWER 25 OF 94  USPATFULL on STN
```

MMP-13 inhibitors

TI Metalloproteinase inhibitors, pharmaceutical compositions containing them, and their use
AN 2001:185326 USPATFULL
TI Metalloproteinase inhibitors, pharmaceutical compositions containing them, and their use
IN Bender, Steven L., Oceanside, CA, United States
Castelhano, Arlindo L., New City, NY, United States
Chong, Wesley K. M., Encinitas, CA, United States
Abreo, Melwyn A., Imperial Beach, CA, United States
Billedeau, Roland J., Santa Clara, CA, United States
Chen, Jian Jeffrey, Santa Clara, CA, United States
Deal, Judith G., Temecula, CA, United States
PA Agouron Pharmaceuticals, Inc., La Jolla, CA, United States (U.S. corporation)
Syntex Inc., Palo Alto, CA, United States (U.S. corporation)
PI US 6306892 B1 20011023 <--
AI US 2000-598208 20000621 (9)
RLI Division of Ser. No. US 1999-309602, filed on 11 May 1999, now patented, Pat. No. US 6174915 Division of Ser. No. US 1997-823962, filed on 25 Mar 1997, now patented, Pat. No. US 6008243
PRAI US 1996-29115P 19961024 (60)
DT Utility
FS GRANTED
EXNAM Primary Examiner: Aulakh, Charanjit S.
CLMN Number of Claims: 20
ECL Exemplary Claim: 1
DRWN No Drawings
LN.CNT 6478
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L10 ANSWER 26 OF 94 USPATFULL on STN
TI Arylsulfonylamino hydroxamic acid derivatives
AN 2001:179128 USPATFULL
TI Arylsulfonylamino hydroxamic acid derivatives
IN Robinson, Jr., Ralph Pelton, Gales Ferry, CT, United States
McClure, Kim Francis, Mystic, CT, United States
PA Pfizer Inc, New York, NY, United States (U.S. corporation)
PI US 6303636 B1 20011016 <--
WO 9833768 19980806 <--
AI US 1999-355163 19990722 (9)
WO 1998-IB23 19980112
19990722 PCT 371 date
19990722 PCT 102(e) date
PRAI US 1997-36857P 19970203 (60)
DT Utility
FS GRANTED
EXNAM Primary Examiner: Chang, Ceila
LREP Richardson, Peter C., Ginsburg, Paul H., Butterfield, Garth
CLMN Number of Claims: 8
ECL Exemplary Claim: 1
DRWN No Drawings
LN.CNT 980
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L10 ANSWER 27 OF 94 USPATFULL on STN
TI Bicycliccarbonyl indole compounds as anti-inflammatory/analgesic agents
AN 2001:179120 USPATFULL
TI Bicycliccarbonyl indole compounds as anti-inflammatory/analgesic agents
IN Nakao, Kazunari, Chita-Gun, Japan
Hayashi, Shigeo, Chita-Gun, Japan
Stevens, Rodney W., Chita-Gun, Japan
PA Pfizer Inc, New York, NY, United States (U.S. corporation)
PI US 6303628 B1 20011016 <--

MMP-13 inhibitors

AI US 2000-605811 20000628 (9)
RLI Continuation of Ser. No. WO 1999-IB1243, filed on 2 Jul 1999
DT Utility
FS GRANTED
EXNAM Primary Examiner: Davis, Zinna Northington
LREP Richardson, Peter C., Ginsburg, Paul H., Djuardi, Elsa
CLMN Number of Claims: 12
ECL Exemplary Claim: 1
DRWN No Drawings
LN.CNT 1846

L10 ANSWER 28 OF 94 USPATFULL on STN
TI Preparation and use of ortho-sulfonamido bicyclic heteroaryl hydroxamic acids as matrix metalloproteinase and tace inhibitors
AN 2001:165837 USPATFULL
TI Preparation and use of ortho-sulfonamido bicyclic heteroaryl hydroxamic acids as matrix metalloproteinase and tace inhibitors
IN Levin, Jeremy I., Nanuet, NY, United States
Zask, Arie, New York, NY, United States
Gu, Yansong, Pearl River, NY, United States
Albright, Jay D., Nanuet, NY, United States
Du, Xuemei, Valley Cottage, NY, United States
PI US 2001025047 A1 20010927 <--
US 6498167 B2 20021224
AI US 2000-734056 A1 20001211 (9)
RLI Division of Ser. No. US 1998-59554, filed on 14 Apr 1998, GRANTED, Pat. No. US 6228869 Continuation-in-part of Ser. No. US 1998-55856, filed on 6 Apr 1998, ABANDONED Continuation-in-part of Ser. No. US 1997-944188, filed on 6 Oct 1997, ABANDONED
PRAI US 1996-28505P 19961016 (60)
DT Utility
FS APPLICATION
LREP Ronald W. Alice, American Home Products Corporation, Patent Law Department - 2B, One Campus Drive, Parsippany, NJ, 07054
CLMN Number of Claims: 12
ECL Exemplary Claim: 1
DRWN No Drawings
LN.CNT 2510
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L10 ANSWER 29 OF 94 USPATFULL on STN
TI Sulfonylbenzene compounds as anti-inflammatory/analgesic agents
AN 2001:163224 USPATFULL
TI Sulfonylbenzene compounds as anti-inflammatory/analgesic agents
IN Ando, Kazuo, Chita-gun, Japan
Kato, Tomoki, Chita-gun, Japan
Kawai, Akiyoshi, Chita-gun, Japan
Nonomura, Tomomi, Chita-gun, Japan
PA Pfizer Inc., New York, NY, United States (U.S. corporation)
PI US 6294558 B1 20010925 <--
WO 9711704 19970403 <--
AI US 1999-446049 19991215 (9)
WO 1999-IB970 19990531
19991215 PCT 371 date
19991215 PCT 102(e) date
DT Utility
FS GRANTED
EXNAM Primary Examiner: Raymond, Richard L.; Assistant Examiner: Patel, Sudhaker B.
LREP Richardson, Peter C., Ginsburg, Paul H., Looney, Adrian G.
CLMN Number of Claims: 30
ECL Exemplary Claim: 1
DRWN No Drawings

MMP-13 inhibitors

LN.CNT 8683
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L10 ANSWER 30 OF 94 USPATFULL on STN
TI Heterocyclic hydroxamic acid derivatives as MMP inhibitors
AN 2001:163207 USPATFULL
TI Heterocyclic hydroxamic acid derivatives as MMP inhibitors
IN Lou, Boliang, Louisville, KY, United States
Mjalli, Adnan M. M., Jamestown, NC, United States
PA Advanced Syntech, LLC, Louisville, KY, United States (U.S. corporation)
PI US 6294539 B1 20010925 <--
AI US 2000-487528 20000119 (9)
PRAI US 1999-116250P 19990119 (60)
DT Utility
FS GRANTED
EXNAM Primary Examiner: Shah, Mukund J.; Assistant Examiner: Patel, Sudhaker B.
LREP Vanderburgh, John E.
CLMN Number of Claims: 10
ECL Exemplary Claim: 1
DRWN No Drawings
LN.CNT 1015
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L10 ANSWER 31 OF 94 USPATFULL on STN
TI Procollagen C-proteinase inhibitors
AN 2001:155784 USPATFULL
TI Procollagen C-proteinase inhibitors
IN Bailey, Simon, County of Kent, Great Britain
Billotte, Stephane, County of Kent, Great Britain
Derrick, Andrew Michael, County of Kent, Great Britain
Fish, Paul Vincent, County of Kent, Great Britain
James, Kim, County of James, Great Britain
Thomson, Nicholas Murray, County of Kent, Great Britain
PI US 2001021718 A1 20010913 <--
US 6448278 B2 20020910
AI US 2000-735968 A1 20001213 (9)
PRAI GB 1999-30570 19991223
US 2000-180527P 20000207 (60)
DT Utility
FS APPLICATION
LREP Paul H. Ginsburg, Pfizer Inc, 235 East 42nd Street, 20th Floor, New York, NY, 10017-5755
CLMN Number of Claims: 53
ECL Exemplary Claim: 1
DRWN No Drawings
LN.CNT 5478
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L10 ANSWER 32 OF 94 USPATFULL on STN
TI N-hydroxy-2-(alkyl, aryl, or heteroaryl, sulfanyl, sulfinyl or sulfonyl)-3-substituted alkyl, aryl or heteroarylamides as matrix metalloproteinase inhibitors
AN 2001:152983 USPATFULL
TI N-hydroxy-2-(alkyl, aryl, or heteroaryl, sulfanyl, sulfinyl or sulfonyl)-3-substituted alkyl, aryl or heteroarylamides as matrix metalloproteinase inhibitors
IN Venkatesan, Aranapakam Mudumbai, Rego Park, NY, United States
PA American Cyanamid Company, Madison, NJ, United States (U.S. corporation)
PI US 6288086 B1 20010911 <--
AI US 2000-593918 20000614 (9)
RLI Division of Ser. No. US 1998-140504, filed on 26 Aug 1998, now patented, Pat. No. US 6197791 Continuation-in-part of Ser. No. US 1998-26372,

MMP-13 inhibitors

filed on 19 Feb 1998, now abandoned
PRAI US 1997-38899P 19970227 (60)
DT Utility
FS GRANTED
EXNAM Primary Examiner: Aulakh, Charanjit
LREP Hogan, Jr., John W.
CLMN Number of Claims: 9
ECL Exemplary Claim: 1
DRWN No Drawings
LN.CNT 6559
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L10 ANSWER 33 OF 94 USPATFULL on STN
TI Diagnostic method for detection of periodontitis or peri-implantitis
AN 2001:141837 USPATFULL
TI Diagnostic method for detection of periodontitis or peri-implantitis
IN Golub, Lorne M., Smithtown, NY, United States
Sorsa, Timo, Helsinki, Finland
Teronen, Olli, Helsinki, Finland
Tikanoja, Sari Hannele, Helsinki, Finland
PA The Research Foundation of State University of NY, Albany, NY, United States (U.S. corporation)
Medix Biochemica, Kauniainen, Finland (non-U.S. corporation)
PI US 6280687 B1 20010828 <--
AI US 2000-642380 20000821 (9)
RLI Division of Ser. No. US 1998-133887, filed on 13 Aug 1998, now patented, Pat. No. US 6143506
DT Utility
FS GRANTED
EXNAM Primary Examiner: Stucker, Jeffrey
LREP Hoffmann & Baron, LLP
CLMN Number of Claims: 18
ECL Exemplary Claim: 1
DRWN 8 Drawing Figure(s); 7 Drawing Page(s)
LN.CNT 1767
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L10 ANSWER 34 OF 94 USPATFULL on STN
TI Acetylenic aryl sulfonamide and phosphinic acid amide hydroxamic acid TACE inhibitors
AN 2001:136688 USPATFULL
TI Acetylenic aryl sulfonamide and phosphinic acid amide hydroxamic acid TACE inhibitors
IN Levin, Jeremy I., New City, NY, United States
Chen, James M., Stoddard Court, NJ, United States
PA American Cyanamid Company, Madison, NJ, United States (U.S. corporation)
PI US 6277885 B1 20010821 <--
AI US 2000-491636 20000127 (9)
PRAI US 1999-155204P 19990127 (60)
DT Utility
FS GRANTED
EXNAM Primary Examiner: Raymond, Richard L.
LREP Hogan, Jr., John W.
CLMN Number of Claims: 13
ECL Exemplary Claim: 1
DRWN No Drawings
LN.CNT 2073
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L10 ANSWER 35 OF 94 USPATFULL on STN
TI Substituted indole compounds as anti-inflammatory and analgesic agents
AN 2001:136681 USPATFULL
TI Substituted indole compounds as anti-inflammatory and analgesic agents

MMP-13 inhibitors

IN Nakao, Kazunari, Chita-gun, Japan
Stevens, Rodney W., Chita-gun, Japan
Kawamura, Kiyoshi, Chita-gun, Japan
Uchida, Chikara, Chita-gun, Japan
PA Pfizer Inc, New York, NY, United States (U.S. corporation)
PI US 6277878 B1 20010821 <--
AI US 1999-383353 19990826 (9)
PRAI WO 1998-IB1382 19980907
DT Utility
FS GRANTED
EXNAM Primary Examiner: Raymond, Richard L.; Assistant Examiner: Liu, Hong
LREP Richardson, Peter C., Ginsburg, Paul H., Djuardi, Elsa
CLMN Number of Claims: 11
ECL Exemplary Claim: 1
DRWN No Drawings
LN.CNT 2629
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L10 ANSWER 36 OF 94 USPATFULL on STN
TI AROMATIC SULFONE HYDROXAMIC ACID METALLOPROTEASE INHIBITOR
AN 2001:134239 USPATFULL
TI AROMATIC SULFONE HYDROXAMIC ACID METALLOPROTEASE INHIBITOR
IN BARTA, THOMAS E., EVANSTON, IL, United States
BECKER, DANIEL P., GLENVIEW, IL, United States
BOEHM, TERRI L., BALLWIN, MO, United States
DECRESCENZO, GARY A., ST.CHARLES, MO, United States
WILLAMIL, CLARA I., GLENVIEW, IL, United States
MCDONALD, JOSEPH J., BALLWIN, MO, United States
FRESKOS, JOHN N., CLAYTON, MO, United States
GETMAN, DANIEL P., CHESTERFIELD, MO, United States
HANSON, GUNNAR J., STOKIE, IL, United States
PI US 2001014688 A1 20010816 <--
AI US 1998-191129 A1 19981113 (9)
PRAI US 1997-66007P 19971114 (60)
US 1998-95347P 19980804 (60)
US 1998-95501P 19980806 (60)
DT Utility
FS APPLICATION
LREP WELSH AND KATZ, 120 SOUTH RIVERSIDE PLAZA, 22ND FLOOR, CHICAGO, IL, 606063913
CLMN Number of Claims: 142
ECL Exemplary Claim: 1
DRWN No Drawings
LN.CNT 15774
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L10 ANSWER 37 OF 94 USPATFULL on STN
TI Process for preparing phenoxyphenylsulfonyl halides
AN 2001:123634 USPATFULL
TI Process for preparing phenoxyphenylsulfonyl halides
IN Hawkins, Joel M., Old Lyme, CT, United States
PI US 2001011143 A1 20010802 <--
AI US 2000-740398 A1 20001219 (9)
RLI Continuation of Ser. No. US 2000-503460, filed on 14 Feb 2000, PENDING
Continuation of Ser. No. US 1999-287930, filed on 7 Apr 1999, GRANTED, Pat. No. US 6118016
PRAI US 1998-81393P 19980410 (60)
DT Utility
FS APPLICATION
LREP Paul H. Ginsburg, Esq., Pfizer Inc, Patent Dept., 20th Floor, 235 East 42nd Street, New York, NY, 10017-5755
CLMN Number of Claims: 15
ECL Exemplary Claim: 1

MMP-13 inhibitors

DRWN No Drawings
LN.CNT 646
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L10 ANSWER 38 OF 94 USPATFULL on STN
TI Aryloxy-alkyl-dialkylamines
AN 2001:121611 USPATFULL
TI Aryloxy-alkyl-dialkylamines
IN Raveendranath, Panolil, Monroe, NY, United States
Zeldis, Joseph, New City, NY, United States
Vid, Galina, New City, NY, United States
Potoski, John R., West Nyack, NY, United States
Ren, Jianxin, Tenafly, NJ, United States
Iera, Silvio, Montreal, Canada
PA American Home Products Corporation, Madison, NJ, United States (U.S. corporation)
PI US 6268504 B1 20010731 <--
AI US 1999-458317 19991210 (9)
RLI Division of Ser. No. US 1998-161653, filed on 28 Sep 1998, now patented, Pat. No. US 6005102
DT Utility
FS GRANTED
EXNAM Primary Examiner: Higel, Floyd D.; Assistant Examiner: Sackey, Ebenezer
LREP Eck, Steven R.
CLMN Number of Claims: 9
ECL Exemplary Claim: 1
DRWN No Drawings
LN.CNT 1710
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L10 ANSWER 39 OF 94 USPATFULL on STN
TI Human neutrophil collagenase splice variant
AN 2001:100857 USPATFULL
TI Human neutrophil collagenase splice variant
IN Hu, Shou-Ih, New Providence, NJ, United States
PA Novartis AG, Basel, Switzerland (non-U.S. corporation)
PI US 1973 H1 20010703 <--
AI US 1998-178002 19981022 (9)
DT Statutory
FS GRANTED
EXNAM Primary Examiner: Carone, Michael J.; Assistant Examiner: Baker, Aileen J.
LREP Ferraro, Gregory D.
CLMN Number of Claims: 31
ECL Exemplary Claim: 1
DRWN 5 Drawing Figure(s); 3 Drawing Page(s)
LN.CNT 1628
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L10 ANSWER 40 OF 94 USPATFULL on STN
TI Aryloxy-alkyl-dialkylamines
AN 2001:82930 USPATFULL
TI Aryloxy-alkyl-dialkylamines
IN Raveendranath, Panolil, Monroe, NY, United States
Zeldis, Joseph, New City, NY, United States
Vid, Galina, New City, NY, United States
Potoski, John R., West Nyack, NY, United States
Ren, Jianxin, Tenafly, NJ, United States
Iera, Silvio, Montreal, Canada
PA American Home Products Corporation, Madison, NJ, United States (U.S. corporation)
PI US 6242605 B1 20010605 <--
AI US 1999-458316 19991210 (9)

MMP-13 inhibitors

RLI Division of Ser. No. US 1998-161653, filed on 28 Sep 1998, now patented, Pat. No. US 6005102
PRAI US 1997-90099P 19971015 (60)
DT Utility
FS Granted
EXNAM Primary Examiner: Higel, Floyd D.; Assistant Examiner: Sackey, Ebenezer
LREP Eck, Steven R.
CLMN Number of Claims: 9
ECL Exemplary Claim: 1
DRWN No Drawings
LN.CNT 1715
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

=> logoff
ALL L# QUERIES AND ANSWER SETS ARE DELETED AT LOGOFF
LOGOFF? (Y)/N/HOLD:y

COST IN U.S. DOLLARS	SINCE FILE ENTRY	TOTAL SESSION
FULL ESTIMATED COST	35.01	92.89

DISCOUNT AMOUNTS (FOR QUALIFYING ACCOUNTS)	SINCE FILE ENTRY	TOTAL SESSION
CA SUBSCRIBER PRICE	0.00	-1.50

STN INTERNATIONAL LOGOFF AT 11:39:32 ON 30 MAR 2006

MMP-13 inhibitors

Connecting via Winsock to STN

Welcome to STN International! Enter x:x

LOGINID:SSPTAEXO1623

PASSWORD:
TERMINAL (ENTER 1, 2, 3, OR ?):2

* * * * * * * * * * Welcome to STN International * * * * * * * * * *

NEWS	1		Web Page URLs for STN Seminar Schedule - N. America
NEWS	2		"Ask CAS" for self-help around the clock
NEWS	3	DEC 21	IPC search and display fields enhanced in CA/CAplus with the IPC reform
NEWS	4	DEC 23	New IPC8 SEARCH, DISPLAY, and SELECT fields in USPATFULL/ USPAT2
NEWS	5	JAN 13	IPC 8 searching in IFIPAT, IFIUDB, and IFICDB
NEWS	6	JAN 13	New IPC 8 SEARCH, DISPLAY, and SELECT enhancements added to INPADOC
NEWS	7	JAN 17	Pre-1988 INPI data added to MARPAT
NEWS	8	JAN 17	IPC 8 in the WPI family of databases including WPIFV
NEWS	9	JAN 30	Saved answer limit increased
NEWS	10	JAN 31	Monthly current-awareness alert (SDI) frequency added to TULSA
NEWS	11	FEB 21	STN AnaVist, Version 1.1, lets you share your STN AnaVist visualization results
NEWS	12	FEB 22	Status of current WO (PCT) information on STN
NEWS	13	FEB 22	The IPC thesaurus added to additional patent databases on STN
NEWS	14	FEB 22	Updates in EPFULL; IPC 8 enhancements added
NEWS	15	FEB 27	New STN AnaVist pricing effective March 1, 2006
NEWS	16	FEB 28	MEDLINE/LMEDLINE reload improves functionality
NEWS	17	FEB 28	TOXCENTER reloaded with enhancements
NEWS	18	FEB 28	REGISTRY/ZREGISTRY enhanced with more experimental spectral property data
NEWS	19	MAR 01	INSPEC reloaded and enhanced
NEWS	20	MAR 03	Updates in PATDPA; addition of IPC 8 data without attributes
NEWS	21	MAR 08	X.25 communication option no longer available after June 2006
NEWS	22	MAR 22	EMBASE is now updated on a daily basis

NEWS EXPRESS FEBRUARY 15 CURRENT VERSION FOR WINDOWS IS V8.01a, CURRENT MACINTOSH VERSION IS V6.0c(ENG) AND V6.0Jc(JP), AND CURRENT DISCOVER FILE IS DATED 19 DECEMBER 2005. V8.0 AND V8.01 USERS CAN OBTAIN THE UPGRADE TO V8.01a AT http://download.cas.org/express/v8.0-Discover/

NEWS HOURS STN Operating Hours Plus Help Desk Availability
NEWS LOGIN Welcome Banner and News Items

Enter NEWS followed by the item number or name to see news on that specific topic.

MMP-13 inhibitors

```
  * * * * * * * * * * * * * * STN  Columbus  * * * * * * * * * * * * * * * *

FILE 'HOME' ENTERED AT 12:40:17 ON 30 MAR 2006

=> file caplus
COST IN U.S. DOLLARS                                    SINCE FILE      TOTAL
                                                           ENTRY    SESSION
FULL ESTIMATED COST                                         0.21       0.21

FILE 'CAPLUS' ENTERED AT 12:41:02 ON 30 MAR 2006
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.
COPYRIGHT (C) 2006 AMERICAN CHEMICAL SOCIETY (ACS)
```



```
FILE COVERS 1907 - 30 Mar 2006  VOL 144 ISS 14
FILE LAST UPDATED: 29 Mar 2006  (20060329/ED)

Effective October 17, 2005, revised CAS Information Use Policies apply.
They are available for your review at:

http://www.cas.org/infopolicy.html

=> s MMP-13(inhibitor)
MISSING OPERATOR 'MMP-13(INHIBITOR'
The search profile that was entered contains terms or
nested terms that are not separated by a logical operator.

=> s MMP-13(w)inhibitor
         13340 MMP
        813714 13
           982 MMP-13
                 (MMP(W)13)
        501944 INHIBITOR
L1          21 MMP-13(W)INHIBITOR

=> s L1 and py<2002
      21808396 PY<2002
L2            4 L1 AND PY<2002

=> d 1-4 ti

L2   ANSWER 1 OF 4  CAPLUS  COPYRIGHT 2006 ACS on STN
TI   The discovery of anthranilic acid-based MMP inhibitors. Part 2: SAR of the
     5-position and P11 groups

L2   ANSWER 2 OF 4  CAPLUS  COPYRIGHT 2006 ACS on STN
TI   Structure-Based Design of a Novel, Potent, and Selective Inhibitor for
     MMP-13 Utilizing NMR Spectroscopy and Computer-Aided Molecular Design

L2   ANSWER 3 OF 4  CAPLUS  COPYRIGHT 2006 ACS on STN
TI   Broad antitumor and antiangiogenic activities of AG3340, a potent and
     selective MMP inhibitor undergoing advanced oncology clinical trials
```

MMP-13 inhibitors

L2 ANSWER 4 OF 4 CAPLUS COPYRIGHT 2006 ACS on STN
TI synthesis and identification of conformationally constrained selective MMP inhibitors

=> d 1-4 ti abs bib

L2 ANSWER 1 OF 4 CAPLUS COPYRIGHT 2006 ACS on STN
TI The discovery of anthranilic acid-based MMP inhibitors. Part 2: SAR of the 5-position and P11 groups
GI



I

AB A novel series of anthranilic acid-based inhibitors of MMP-1, MMP-9, MMP-13, and TACE was prepared and evaluated. Selective inhibitors of MMP-9, MMP-13, and TACE were identified, including the potent, orally active **MMP-13 inhibitor** I.
AN 2001:612039 CAPLUS
DN 136:163
TI The discovery of anthranilic acid-based MMP inhibitors. Part 2: SAR of the 5-position and P11 groups
AU Levin, J. I.; Chen, J.; Du, M.; Hogan, M.; Kincaid, S.; Nelson, F. C.; Venkatesan, A. M.; Wehr, T.; Zask, A.; DiJoseph, J.; Killar, L. M.; Skala, S.; Sung, A.; Sharr, M.; Roth, C.; Jin, G.; Cowling, R.; Mohler, K. M.; Black, R. A.; March, C. J.; Skotnicki, J. S.
CS Wyeth-Ayerst Research, Pearl River, NY, 10965, USA
SO Bioorganic & Medicinal Chemistry Letters (**2001**), 11(16), 2189-2192
CODEN: BMCLE8; ISSN: 0960-894X
PB Elsevier Science Ltd.
DT Journal
LA English
RE.CNT 21 THERE ARE 21 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L2 ANSWER 2 OF 4 CAPLUS COPYRIGHT 2006 ACS on STN
TI Structure-Based Design of a Novel, Potent, and Selective Inhibitor for MMP-13 Utilizing NMR Spectroscopy and Computer-Aided Molecular Design
AB The high-resolution NMR solution structure of the catalytic fragment of human collagenase-3 (MMP-13) was used as a starting point for structure-based design of selective inhibitors for MMP-13. The major structural difference observed between the MMP structures is the relative size and shape of the S1' pocket where this pocket is significantly longer for MMP-13, nearly reaching the surface of the protein. On the basis of the extended nature of the MMP-13 S1' pocket an inhibitor potent and selective for MMP-13 was designed from an initial high throughput screening (HTS) lead. CL-82198 was identified as a weak (10 μM) inhibitor against MMP-13 while demonstrating no activity against MMP-1, MMP-9, or the related enzyme TACE. The drug-like properties of CL-82198 made it an ideal candidate for optimization of enzyme potency and selectivity. On the basis of NMR binding studies, it was shown that inhibitor CL-82198 bound

within the entire S1' pocket of MMP-13 which is the basis of its selectivity against MMP-1, MMP-9, and TACE. A strategy utilizing this information was devised for designing new inhibitors that showed enhanced selectivity toward MMP-13. Our design strategy combined the critical selectivity features of CL-82198 with the known potency features of a nonspecific MMP inhibitor (WAY-152177) to generate a potent and selective **MMP-13 inhibitor** (WAY-170523). WAY-170523 has an IC50 of 17 nM for MMP-13 and showed >5800-, 56-, and >500-fold selectivity against MMP-1, MMP-9, and TACE, resp.

AN 2000:662531 CAPLUS
DN 133:360381
TI Structure-Based Design of a Novel, Potent, and Selective Inhibitor for MMP-13 Utilizing NMR Spectroscopy and Computer-Aided Molecular Design
AU Chen, James M.; Nelson, Frances C.; Levin, Jeremy I.; Mobilio, Dominick; Moy, Franklin J.; Nilakantan, Ramaswamy; Zask, Arie; Powers, Robert
CS Department of Biological Chemistry Wyeth Research, Wyeth Research, Cambridge, MA, 02140, USA
SO Journal of the American Chemical Society (**2000**), 122(40), 9648-9654
CODEN: JACSAT; ISSN: 0002-7863
PB American Chemical Society
DT Journal
LA English
RE.CNT 55 THERE ARE 55 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L2 ANSWER 3 OF 4 CAPLUS COPYRIGHT 2006 ACS on STN
TI Broad antitumor and antiangiogenic activities of AG3340, a potent and selective MMP inhibitor undergoing advanced oncology clinical trials
AB We studied AG3340, a potent metalloproteinase (MMP) inhibitor with pM affinities for inhibiting gelatinases (MMP-2 and -9), MT-MMP-1 (MMP-14), and collagenase-3 (MMP-13) in many tumor models. AG3340 produced dose-dependent pharmacokinetics and was well tolerated after i.p. (i.p.) and oral dosing in mice. Across human tumor models, AG3340 produced profound tumor growth delays when dosing began early or late after tumor implantation, although all established tumor types did not respond to AG3340. A dose-response relationship was explored in three models: COLO-320DM colon, MV522 lung, and MDA-MB-435 breast. Dose-dependent inhibitions of tumor growth (over 12.5-200 mg/kg given twice daily, b.i.d.) were observed in the colon and lung models; and in a third (breast), maximal inhibitions were produced by the lowest dose of AG3340 (50 mg/kg, b.i.d.) that was tested. In another model, AG3340 (100 mg/kg, once daily, i.p.) markedly inhibited U87 glioma growth and increased animal survival. AG3340 also inhibited tumor growth and increased the survival of nude mice bearing androgen-independent PC-3 prostatic tumors. In a sixth model, KKLS gastric, AG3340 did not inhibit tumor growth but potentiated the efficacy of Taxol. Importantly, AG3340 markedly decreased tumor angiogenesis (as assessed by CD-31 staining) and cell proliferation (as assessed by bromodeoxyuridine incorporation), and increased tumor necrosis and apoptosis (as assessed by hematoxylin and eosin and TUNEL staining). These effects were model dependent, but angiogenesis was commonly inhibited. AG3340 had a superior therapeutic index to the cytotoxic agents, carboplatin and Taxol, in the MV522 lung cancer model. In combination, AG3340 enhanced the efficacy of these cytotoxic agents without altering drug tolerance. Addnl., AG3340 decreased the number of murine melanoma (B16-F10) lesions arising in the lung in an i.v. metastasis model when given in combination with carboplatin or Taxol. These studies directly support the use of AG3340 in front-line combination chemotherapy in ongoing clin. trials in patients with advanced malignancies of the lung and prostate.
AN 1999:473511 CAPLUS
DN 131:139010
TI Broad antitumor and antiangiogenic activities of AG3340, a potent and

MMP-13 inhibitors

selective MMP inhibitor undergoing advanced oncology clinical trials
AU Shalinsky, D. R.; Brekken, J.; Zou, H.; McDermott, C. D.; Forsyth, P.; Edwards, D.; Margosiak, S.; Bender, S.; Truitt, G.; Wood, A.; Varki, N. M.; Appelt, K.
CS Departments of Pharmacology, Agouron Pharmaceuticals, Inc., San Diego, CA, 92121, USA
SO Annals of the New York Academy of Sciences (**1999**), 878(Inhibition of Matrix Metalloproteinases), 236-270
CODEN: ANYAA9; ISSN: 0077-8923
PB New York Academy of Sciences
DT Journal
LA English
RE.CNT 72 THERE ARE 72 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L2 ANSWER 4 OF 4 CAPLUS COPYRIGHT 2006 ACS on STN
TI synthesis and identification of conformationally constrained selective MMP inhibitors
AB A new series of potent conformationally constrained MMP inhibitors that are selective for MMP-13 over MMP-1 was discovered.
AN 1999:429268 CAPLUS
DN 131:199456
TI synthesis and identification of conformationally constrained selective MMP inhibitors
AU Freskos, John N.; McDonald, Joseph J.; Mischke, Brent V.; Mullins, Patrick B.; Shieh, Huey-Sheng; Stegeman, Roderick A.; Stevens, Anna M.
CS Department of Medicinal Chemistry, Searle Discovery Research, St Louis, MO, 63198, USA
SO Bioorganic & Medicinal Chemistry Letters (**1999**), 9(13), 1757-1760
CODEN: BMCLE8; ISSN: 0960-894X
PB Elsevier Science Ltd.
DT Journal
LA English
RE.CNT 6 THERE ARE 6 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

=> FIL STNGUIDE

COST IN U.S. DOLLARS	SINCE FILE ENTRY	TOTAL SESSION
FULL ESTIMATED COST	21.46	21.67

DISCOUNT AMOUNTS (FOR QUALIFYING ACCOUNTS)	SINCE FILE ENTRY	TOTAL SESSION
CA SUBSCRIBER PRICE	-3.00	-3.00

FILE 'STNGUIDE' ENTERED AT 12:42:47 ON 30 MAR 2006
USE IS SUBJECT TO THE TERMS OF YOUR CUSTOMER AGREEMENT
COPYRIGHT (C) 2006 AMERICAN CHEMICAL SOCIETY, JAPAN SCIENCE AND TECHNOLOGY CORPORATION, AND FACHINFORMATIONSZENTRUM KARLSRUHE

FILE CONTAINS CURRENT INFORMATION.
LAST RELOADED: Mar 24, 2006 (20060324/UP).

=> logoff
ALL L# QUERIES AND ANSWER SETS ARE DELETED AT LOGOFF
LOGOFF? (Y)/N/HOLD:y

COST IN U.S. DOLLARS	SINCE FILE ENTRY	TOTAL SESSION
FULL ESTIMATED COST	0.06	21.73

DISCOUNT AMOUNTS (FOR QUALIFYING ACCOUNTS)	SINCE FILE	TOTAL

MMP-13 inhibitors

	ENTRY	SESSION
CA SUBSCRIBER PRICE	0.00	-3.00

STN INTERNATIONAL LOGOFF AT 12:43:02 ON 30 MAR 2006